

## CORPORATE GOVERNANCE REPORT

The Board of Directors (the “**Board**” or the “**Directors**”) of Rex International Holding Limited (the “**Company**” and together with its subsidiaries, the “**Group**”) is committed to achieving and maintaining high standards of corporate governance principles and processes in managing its business and affairs to enhance long-term shareholder value and business performance, by embracing the tenets of good governance, including accountability, transparency and sustainability of the Group.

During the financial year under review, the Directors of the Company have reviewed its corporate governance practices and ensured that they are in compliance with the applicable provisions of the Code of Corporate Governance 2018 (the “**Code**”) issued by the Monetary Authority of Singapore and the applicable listing rules of the Singapore Exchange Securities Trading Limited (the “**SGX-ST**”) (the “**Listing Rules**”). Where applicable, deviations from the Code have been explained and how the Group’s practices are consistent with the intent of the relevant principles.

This corporate governance report sets out how the Company has applied the principles of good corporate governance in a disclosure-based regime where the accountability of the Board to the Company’s shareholders and the Management to the Board provides a framework for achieving a mutually beneficial tripartite relationship aimed at creating, enhancing and growing sustainable shareholders’ value.

### GUIDELINE

General

#### *Compliance to the Code*

The Company has complied with the principles and provisions as set out in the Code and the disclosure guide developed by the SGX-ST in 2018 (the “**Guide**”), where applicable. Appropriate explanations have been provided in the relevant sections below where there are deviations from the Code.

### BOARD MATTERS

#### The Board’s Conduct of Affairs

**Principle 1** *The company is headed by an effective Board which is collectively responsible and works with Management for the long-term success of the company.*

1.1

#### *Role of the Board*

##### *Composition of the Board*

<b>Name of Director</b>	<b>Designation</b>
Dan Broström	Executive Chairman
Dr Karl Lidgren	Executive Director
Sin Boon Ann	Lead Independent Non-Executive Director
Dr Christopher Atkinson	Independent Non-Executive Director
Mae Heng	Independent Non-Executive Director
John d’Abo	Independent Non-Executive Director
Dr Mathias Lidgren	Non-Independent Non-Executive Director

The Company’s Board is committed to achieving and maintaining high standards of corporate governance principles and processes in managing its business and affairs to enhance long-term shareholder value and business performance, by embracing the tenets of good governance, including accountability, transparency and sustainability of the Group.

## CORPORATE GOVERNANCE REPORT

The Board sees as its role to:

- (a) Provide entrepreneurial leadership guidance, set corporate strategic objectives and directions for Management, which should include appropriate focus on value creation, innovation and sustainability;
- (b) Set the appropriate tone-from-the-top and desired organisational culture, and to ensure proper accountability within the Company;
- (c) Ensure that the necessary resources are in place for the Company to meet its strategic objectives;
- (d) Establish and maintain a sound risk management framework to effectively monitor and manage risks, and to achieve an appropriate balance between risks and company performance;
- (e) Constructively challenge Management and review its performance;
- (f) Instil an ethical corporate culture and ensure that the Company's values, standards, policies and practices are consistent with the culture; and
- (g) Oversee the overall corporate governance of the Group and ensure transparency and accountability to key stakeholder groups.

The Company's Board of Directors Policy sets out the principles and general guidelines for the Directors, who should abide by the policy and any applicable law, legislation, the Listing Rules or the Companies Act. The policy covers aspects including Board composition and balance, Board diversity, tenure and number of directorships, Board member selection and orientation, and code of conduct for the avoidance of conflicts of interest and dealing in the shares of the Company.

### ***Conflicts of Interest***

Specifically, Directors facing conflicts of interest are to recuse themselves from discussions and decisions involving the issues of conflict. The Company has in place a policy on Board of Directors whereby Directors should refrain from having any conflicts of interests with the Company to ensure that their duty to act in the best interest of the Company is not jeopardised. Where the director faces a conflict of interest, he or she should disclose this and recuse himself or herself from discussion and decisions involving the issue. For instance, if the Chairman of the Board (Chairman) is a member of the Nominating Committee ("**NC**"), he or she may face a conflict of interest on discussions relating to the succession of the Chairman and should thus recuse himself or herself from such discussions after providing his or her input to the NC on other matters. This ensures that Directors continually meet the stringent requirements of independence under the Code.

1.2

### ***Director Competencies***

All directors have a good understanding of the Company's business as well as their directorship duties (including their roles as executive, non-executive and independent directors). For future appointments, the Company will provide each newly appointed Director with a formal letter of appointment setting out the Director's role, duties, obligations and responsibilities, and the expectations of their contribution to the Company.

Directors are expected to develop their competencies to effectively discharge their duties and are provided with opportunities to develop and maintain their skills and knowledge at the Company's expense.

## CORPORATE GOVERNANCE REPORT

All newly appointed Directors will undergo an orientation programme where the Director would be briefed on the Group's strategic direction, governance practices, business and organisation structure, and participate in an external course detailing the expected duties of a director of a listed company. To get a better understanding of the Group's business, the Directors will also be given the opportunity to visit the Group's operational facilities and meet with Management, whenever required. A new Director who has no prior experience as a director of an issuer listed on the SGX-ST must also undergo mandatory training in his roles and responsibilities as prescribed by the SGX-ST. All directors are required to undergo a one-time training on sustainability.

Except for Mr Sin Boon Ann and Ms Mae Heng, the rest of the Directors of the Company did not have prior experience holding directorship(s) in public listed companies in Singapore. All of the Directors except for Ms Mae Heng, Mr John d'Abo and Dr Mathias Lidgren, have been on the Company's board for more than seven years. To prepare and familiarise themselves with the roles and responsibilities of Directors of a public listed company, Mr John d'Abo and Dr Mathias Lidgren had completed the Listed Company Director courses conducted by the Singapore Institute of Directors (the "SID") following their appointment to the Board. All directors have also completed the mandatory courses related to sustainability reporting.

Directors are also regularly updated with the latest professional developments in relation to the Listing Rules and other applicable regulatory updates or amendments to relevant laws, rules and regulations to ensure the compliance of the same by all Directors.

In 2022, the Directors attended the following:

<b>Dr Christopher Atkinson</b>	(1)	Singapore Institute of Directors - LED Environmental, Social and Governance Essentials
<b>Dan Broström</b>	(1)	Singapore Institute of Directors - Criticaleye Global Virtual Roundtable: Evaluating the Impact of ESG
	(2)	Singapore Exchange - Fireside Chat with Professor Tommy Koh
	(3)	Singapore Institute of Directors - LED Environmental, Social and Governance Essentials
<b>John d'Abo</b>	(1)	Singapore Institute of Directors - LED1 Listed Entity Director Essentials PART 1
	(2)	Singapore Institute of Directors - LED1 Listed Entity Director Essentials PART 2
	(3)	Singapore Institute of Directors - LED2 Board Dynamics
	(4)	Singapore Institute of Directors - LED3 Board Performance
	(5)	Singapore Institute of Directors - LED4 Stakeholder Engagement
	(6)	Singapore Institute of Directors - LED7 Nominating Committee Essentials
	(7)	Singapore Institute of Directors - LED8 Remuneration Committee Essentials
	(8)	Singapore Institute of Directors - LED Environmental, Social and Governance Essentials
<b>Dr Karl Lidgren</b>	(1)	Singapore Institute of Directors - LED Environmental, Social and Governance Essentials

## CORPORATE GOVERNANCE REPORT

<b>Mae Heng</b>	(1)	Complete Corporate Services and Moore Stephens LLP - Singapore Budget 2022
	(2)	Ernst & Young - Singapore Budget 2022
	(3)	Singapore Institute of Directors - LED Environmental, Social and Governance Essentials
	(4)	Securities Commission Malaysia - Audit Oversight Board Conversation with Audit Committees
	(5)	The Institute of Internal Auditors Singapore - Public Sector Internal Audit (PSIA) Conference 2022: Positioning Internal Audit for the Future
	(6)	Bursa Malaysia - Advocacy Sessions for Directors and Senior Management of Main Market Listed Issuers
	(7)	KPMG - Understanding the requirements in Bursa Malaysia's Enhanced Sustainability Reporting Framework
	(8)	Securities Commission Malaysia - Audit Oversight Board Conversation with Audit Committees
<b>Dr Mathias Lidgren</b>	(1)	Singapore Institute of Directors - LED1: Listed Entity Director Essentials PART 1
	(2)	Singapore Institute of Directors - LED1: Listed Entity Director Essentials PART 2
	(3)	Singapore Institute of Directors - LED2: Board Dynamics
	(4)	Singapore Institute of Directors - LED3: Board Performance
	(5)	Singapore Institute of Directors - LED4: Stakeholder Engagement
	(6)	Singapore Institute of Directors - LED7: Nominating Committee Essentials
	(7)	Singapore Institute of Directors - LED Environmental, Social and Governance Essentials
<b>Sin Boon Ann</b>	(1)	National University of Singapore Faculty of Law - The Role of Precedent in the Construction and Implication of Terms in Contracts by Dr John Eldridge, Serle Court, UK
	(2)	MDD Forensic Accountants - Accounting 101
	(3)	National University of Singapore Faculty of Law - Sat Pal Khattar Professorial Lecture: The Future of Tax Jurisdiction
	(4)	Singapore Management University - Yong Pung How Professorship of Law Lecture 2022 - The Effect of Choice of Court Agreements on Third Parties
	(5)	Singapore Institute of Directors - LED Environmental, Social and Governance Essentials

### 1.3

#### ***Material Transactions Requiring Board Approval***

Matters that require the Board's approval include, amongst others, the following:

- Overall Group business and budget strategy;
- Annual and half-yearly financial reports and announcements on quarterly use of funds/cash by mineral, oil and gas companies;
- Capital expenditures exceeding certain material limits;

## CORPORATE GOVERNANCE REPORT

- Investments or divestments;
- All capital-related matters including capital issuance;
- Significant policies governing the operations of the Company;
- Corporate strategic development and restructuring;
- Interested person transactions exceeding a S\$100,000 threshold; and
- Risk management strategies.

1.4

### **Board Committees**

The Board has delegated certain responsibilities to the Audit Committee (the “**AC**”), the Remuneration Committee (the “**RC**”) and the Nominating Committee (the “**NC**”) (collectively, the “**Board Committees**”). The composition of the Board Committees are as follows:

Board Committee	AC	NC	RC
<b>Designation</b>			
<b>Chairperson</b>	• Mae Heng	• Sin Boon Ann	• Sin Boon Ann
<b>Members</b>	• Dan Broström • Sin Boon Ann	• Dr Karl Lidgren • John d’Abo • Dr Mathias Lidgren	• Dan Broström • John d’Abo

Each Board Committee has clear written terms of reference setting out their compositions, authorities and duties, including reporting back to the Board.

1.5

### **Board and Board Committee Meetings and Attendance**

The Board meets on a quarterly basis, and as and when circumstances require. In the financial year ended 31 December 2022 (“**FY2022**”), the number of Board and Board Committee meetings held and the attendance of each Board member at such meetings as well as at the Annual General Meeting (“**AGM**”) held on 29 April 2022 and the Extraordinary General Meetings (“**EGM**”) held on 3 March 2022 and 29 April 2022 are shown below:

<b>Board, Board Committee and General Meetings in FY 2022</b>						
	Board	AC	NC	RC	AGM	EGM
Number of Meetings Held	4	4	3	3	1	2
Name of Director	Number of Meetings Attended					
Dan Broström	4	4	-	3	1	2
Dr Karl Lidgren	4	-	3	-	1	2
Sin Boon Ann	4	4	3	3	1	2
Muhammad Sameer Yousuf Khan <sup>(1)</sup>	1	1	1	1	1	1
Dr Christopher Atkinson	4	-	-	-	1	2
Mae Heng <sup>(2)</sup>	3	3	-	-	-	-
John d’Abo <sup>(3)</sup>	3	-	2	2	-	-
Dr Mathias Lidgren <sup>(4)</sup>	3	-	2	-	-	-

Notes:

<sup>(1)</sup> Mr Muhammad Sameer Yousuf Khan retired as Independent Non-Executive Director of the Company upon the conclusion of the AGM held on 29 April 2022.

<sup>(2)</sup> Ms Mae Heng was appointed as Independent Non-Executive Director of the Company and Chairperson of the Audit Committee on 4 May 2022.

<sup>(3)</sup> Mr John d’Abo was appointed as Independent Non-Executive Director of the Company and member of the Remuneration and Nominating Committees on 4 May 2022.

<sup>(4)</sup> Dr Mathias Lidgren was appointed as Non-Independent Non-Executive Director of the Company and member of the Nominating Committee on 4 May 2022.

## CORPORATE GOVERNANCE REPORT

To ensure that meetings are held regularly with maximum Directors' participation, the Company's Constitution allows for meetings to be held through telephone and video conferencing software. The Company ensures that telephonic and screen sharing facilities are made available for directors to attend the board meetings.

Regular meetings are held by the Board to deliberate the strategic policies of the Company including significant acquisitions and disposals, review and approve annual budgets, review the performance of the business and approve the public release of periodic financial results. The Board will also convene additional meetings for particular matters as and when they are deemed necessary.

While the Board considers Directors' attendance at Board meetings to be important, it is not the only criterion which the Board uses to measure Directors' contributions. The Board also takes into account the contributions by Board members in other forms including periodical reviews, provision of guidance and advice on various matters relating to the Group.

The responsibility of day-to-day management, administration and operation of the Group are delegated to the Executive Chairman, the Executive Director and the Chief Executive Officer of the Group (the "CEO"). The CEO does not sit on the Board. The CEO has accumulated sufficient and valuable experience to hold his position in order to ensure that his fiduciary duties can be carried out in an effective and efficient manner.

1.6

### ***Complete, Adequate and Timely Information***

Management ensures that all Directors are furnished on an on-going basis with relevant, complete, adequate and timely information concerning the Company, to enable them to make informed decisions and discharge their duties and responsibilities. Information provided to the Board include board papers, copies of disclosure documents, budgets, forecasts, business strategies, risk analyses and assessments, internal financial statements and reports from the internal and external auditors. Most of the information distributed on electronic devices to the Board are password protected for added cyber security. The Board has unrestricted access to the Company's records and information.

Management recognises the importance of circulating information on a timely basis to ensure that the Board has adequate time to review the materials to facilitate a constructive and effective discussion during the scheduled meetings. As such, Management endeavours to circulate information for the Board meetings at least one week prior to the meetings to allow sufficient time for the Directors' review.

1.7

Directors have separate and independent access to Management, the Company Secretary, and external advisers (where necessary) at the Company's expense. The appointment and removal of the Company Secretary is a decision of the Board as a whole.

### ***Board's Independent Access to Management***

Management is available to provide explanatory information in the form of emails, telephone conferences or briefings to the Directors or formal presentations in attendance at Board meetings, or such information can also be provided by external consultants engaged on specific projects. Directors are also provided with the contact details of key management personnel to facilitate direct and independent access to Management.

## CORPORATE GOVERNANCE REPORT

Management will also provide any additional material or information that is requested by Directors or that is necessary to enable the Board to make a balanced and informed decision or assessment of the Group's performance, position and prospects.

Meetings with subsidiaries, partners and consultants through overseas trips are also arranged, whenever possible. The Executive Chairman also provides frequent information updates to other fellow Directors through emails, telephone conferences and informal meetings.

Furthermore, the Management keeps the Board apprised of regulatory updates and implications, as well as significant project updates.

### ***Company Secretary***

The role of the Company Secretary, the appointment and removal of whom is a matter for the Board as a whole, is as follows:

- Ensuring that Board procedures are observed and that the Company's Constitution, relevant rules and regulations, including requirements of the Securities and Futures Act 2001, the Companies Act 1967 and the Listing Rules, are complied with;
- Assisting the Executive Chairman to ensure good information flow within the Board and the Board Committees and Management;
- Attending and preparing minutes for Board meetings;
- Assisting to ensure coordination and liaison between the Board, the Board Committees and Management, in its capacity as secretary to all other Board Committees; and
- Assisting the Executive Chairman, the Chairperson of each Board Committee and Management in the development of the agenda for the various Board and Board Committee meetings.

The Directors have separate and independent access to the Company Secretary.

### ***Independent Professional Advice***

Each Director has the right to seek independent legal and other professional advice, at the Company's expense, concerning any aspect of the Group's operations or undertakings in order to fulfil their duties and responsibilities as Directors.

## **Board Composition and Guidance**

***Principle 2*** ***The Board has an appropriate level of independence and diversity of thought and background in its composition to enable it to make decisions in the best interests of the company.***

2.1

### ***Independent Directors***

The Board takes into account the existence of relationships or circumstances, including those identified by the Code, that are relevant in its determination as to whether a Director is independent.

The NC has reviewed and confirmed the independence of the Independent Directors in accordance with the Code's definition of an "independent director", practice guidance as to the relationships, the existence of which would deem a Director not to be independent and under the applicable Listing Rules. The Independent Directors have also confirmed their independence in accordance with the Code and under the applicable Listing Rules.

## CORPORATE GOVERNANCE REPORT

There is no Director who is deemed independent by the Board, notwithstanding the existence of a relationship as stated in the practice guidance to the Code that would otherwise deem him not to be independent.

### ***Duration of Independent Directors' Tenure***

It is the Company's policy that the submission for re-election of an Independent Director who has served beyond nine years since the date of his or her appointment would be reviewed and approved by the NC.

Mr Sin Boon Ann is the only independent director who has served beyond nine years since the date of his appointment (26 June 2013) (whether before or after listing). His continued appointment as an independent director was passed via two-tier voting by all shareholders and by shareholders, excluding the directors and the chief executive officer of the Company and their associates, at the Company's annual general meeting held on 29 April 2022. Mr Sin Boon Ann remains as independent director until the conclusion of the annual general meeting of the Company for the financial year ending 31 December 2023 pursuant to the Transition Practice Note 4 Transitional Arrangements regarding the Tenure Limit for Independent Directors. The other independent director, Dr Christopher Atkinson, who was appointed to the Board on 6 January 2015, will remain as independent director until the conclusion of the annual general meeting of the Company for the financial year ending 31 December 2023. The Company had put in place a board renewal plan. Independent directors Ms Mae Heng and Mr John d'Abo were appointed to the Board on 4 May 2022.

2.2

### ***Proportion of Independent Non-Executive Directors***

In view that the Executive Chairman is part of the management team and is not an independent director, Provision 2.2 of the Code is met as the Independent Directors make up more than half of the Board since the Company's listing in July 2013.

A majority of four out of seven directors on the Board are Independent Non-Executive Directors.

2.3

### ***Lead Independent Director***

The Company has a lead independent director who plays an additional facilitative role within the Board, and where necessary, may also facilitate communication between the Board and shareholders or other stakeholders of the Company. Please refer to Provision 3.3 of this report for more information.

2.4

### ***Board Diversity***

The Board comprises seven directors: One Executive Chairman, one Executive Director, one Non-Independent Non-executive Director and four Independent Non-Executive Directors, who have the appropriate mix of core competencies and diversity of experience, to direct and lead the Company. There is a good balance between the Executive and Non-Executive Directors, with a strong and independent element on the Board.

The composition of the Board will be reviewed on an annual basis by the NC to ensure that the Board has the appropriate mix of expertise and experience, and collectively possess the necessary core competencies for effective functioning and informed decision-making.



## CORPORATE GOVERNANCE REPORT

The Board's policy in identifying director nominees is primarily to have an appropriate mix of members with complementary skills, core competencies and experience for the Group, regardless of background, gender, ethnicity or nationality. The current seven Board members are of three different nationalities.

The Board is of the view that the current board size is appropriate to effectively facilitate decision making in relation to the operations of the Group, taking into account the nature and scope of the Company's operations, while the Company is transitioning through a board renewal. The Board believes that the current Board members comprise persons whose diverse skills, knowledge, experience, gender, age and attributes provide for an appropriate balance for effective direction for the Group that would avoid groupthink and foster constructive debate. The NC is also of the view that the current Board members comprise persons with a broad range of expertise and experience in diverse areas including accounting, finance, legal, business and management, technology, oil and gas, strategic planning and regional business experience.

In accordance to Rule 710A(1) of the SGX Listing Rules, the Company has in place a board diversity policy, which includes the Board's objectives to ensure that:

- (a) female candidates are included for consideration by the NC whenever it seeks to identify a new director for appointment to the Board; and
- (b) there is appropriate female representation on the Board at any one time from 2023.

The Board has taken the following steps to maintain or enhance its objective to have balance and diversity on the Board:

- Annual review by the NC and periodic engagement of external consultants to assess if the existing attributes and core competencies of the Board are complementary and enhance the efficacy of the Board; and
- Annual evaluation by the Directors of the skill sets the other Directors possess, with a view to understand the range of expertise which is lacking by the Board.

As part of its Board renewal process, the Company appointed two Independent Non-Executive directors and one Non-Independent Non-Executive director in 2022. The Company achieved gender diversity on the Board with the appointment of its first female director to the Board in May 2022.

To meet the changing challenges in the industry and countries which the Group operates in, such reviews and evaluations, which includes considering factors such as the expertise, skills and perspectives which the Board needs against the existing competencies, would be done on an annual basis to ensure that the Board dynamics remain optimal.

The NC will also monitor the implementation of board diversity and report annually on the Board's composition in terms of diversity, in the Company's Corporate Governance Report and will consider the results of these exercises in its recommendation for the appointment of new directors and/or the re-appointment of incumbent directors.

## CORPORATE GOVERNANCE REPORT

### 2.5 ***Non-Executive Director Meetings in Absence of Management***

The Independent Non-Executive Directors constructively challenge and help develop proposals on strategies. From time to time, the Independent Non-Executive Directors, led by any independent director as appropriate, have met in the absence of Management in FY2022 to discuss concerns or matters such as overall Group business strategies and investments. The chairperson of such meetings provides feedback to the Board and/or the Executive Chairman as appropriate.

### **Chairman and Chief Executive Officer**

#### ***Principle 3*** ***There is a clear division of responsibilities between the leadership of the Board and Management, and no one individual has unfettered powers of decision-making.***

### 3.1 ***Segregation of the Role of Chairman and the CEO***

The roles of the Executive Chairman and the CEO are separate to ensure a clear division of their responsibilities, increased accountability and greater capacity of the Board for independent decision making. The Executive Chairman is not related to the CEO and is not a substantial shareholder of the Company.

The Executive Chairman leads and ensures the effectiveness of the Board, and his roles include:

- (a) Promoting a culture of openness and debate at the Board;
- (b) Facilitating the effective contribution of all Directors; and
- (c) Promoting high standards of corporate governance.

The Executive Chairman sets the Board's meeting agenda and ensures the quality, quantity and timeliness of the flow of information between the Board and Management to facilitate efficient decision-making. He chairs the Board meetings and encourages the Board members to present their views on topics under discussion at the meetings in a boardroom culture that promotes open interaction and contributions by all. He also assists in ensuring compliance with the Group's guidelines on corporate governance.

Externally, the Executive Chairman is the face of the Board and ensures effective communication with shareholders and other stakeholders. Within the Company, the Executive Chairman ensures appropriate relations within the Board, and between the Board and Management, in particular, between the Board and the CEO.

The CEO is responsible for the business management and day-to-day operations of the Group. The CEO takes a leading role in developing and expanding the businesses of the Group, including making major business and finance decisions. The CEO also oversees the execution of the Group's business and corporate strategy as set out by the Board and ensures that the Directors are kept updated and informed of the Group's businesses.

## CORPORATE GOVERNANCE REPORT

3.2 The Board has established and set out in writing the division of responsibilities between the Executive Chairman and the CEO. The Executive Chairman's performance and appointment to the Board were reviewed by the NC. The Executive Chairman and CEO's remuneration packages were reviewed by the RC. As the roles of the Executive Chairman and the CEO are separate, and the AC and RC comprise a majority of Independent Directors of the Company, the Board believes that there are adequate safeguards in place to ensure a balance of power and authority, such that no one individual represents a considerable concentration of power.

### 3.3 ***Lead Independent Director***

The Board has a Lead Independent Director, Mr Sin Boon Ann, to provide leadership in situations where the Executive Chairman is conflicted. The appointment of Mr Sin Boon Ann as the Lead Independent Director, where the Executive Chairman is part of the management team and is not an independent director, is in line with the recommendation under Provision 3.3 of the Code. The Lead Independent Director is a key member of the Board, representing the views of the Independent Directors and facilitating a two-way flow of information between shareholders, the Chairman and the Board.

The Lead Independent Director's role may include chairing Board meetings in the absence of the Chairman, working with the Chairman in leading the Board, and providing a channel to non-executive directors for confidential discussions on any concerns and to resolve conflicts of interest as and when necessary.

Mr Sin Boon Ann is also chairman of the NC and the RC. The NC is responsible for conducting annual performance evaluation and development succession plans for the Chairman and CEO; while the RC is responsible for designing and assessing the Chairman's and CEO's remuneration.

The Lead Independent Director also makes himself available at all times when shareholders have concerns and for which contact through the normal channels of communication with the Executive Chairman or Management have failed to resolve or are inappropriate. Submissions can be made to the Lead Independent Director at [independent.director@rexih.com](mailto:independent.director@rexih.com) and will be treated with strictest confidentiality. The Lead Independent Director makes himself available to shareholders at the Company's general meetings.

### ***Independent Director Meetings in Absence of Other Directors***

To facilitate well-balanced viewpoints on the Board, the Lead Independent Director will, where necessary, chair meetings with the Independent Directors without the involvement of other Directors, and the Lead Independent Director will provide feedback to the Executive Chairman after such meetings.

## CORPORATE GOVERNANCE REPORT

### Board Membership

**Principle 4** *The Board has a formal and transparent process for the appointment and re-appointment of Directors to the Board, taking into account the need for progressive renewal of the Board.*

#### 4.1 *Nominating Committee*

The NC is guided by key terms of reference as follows and makes recommendations to the Board on relevant matters relating to:

- (a) The review of succession plans for the Company's Directors, in particular, the appointment and/or replacement of the Executive Chairman, the CEO and key management personnel;
- (b) The process and criteria for evaluation of the performance of the Board, its board committees and directors;
- (c) The review of training and professional development programmes for the Board and its directors;
- (d) The appointment and re-appointment of directors (including alternate directors, if any), in accordance with the Constitution, having regard to the Director's contribution and performance (for example, attendance, preparedness, participation and candour) including, if applicable, as an Independent Non-Executive Director. All Directors shall be required to submit themselves for re-nomination and re-election at regular intervals and at least once every three years;
- (e) Reviewing and approving any new employment of related persons and their proposed terms of employment;
- (f) Determining annually, and as and when circumstances require, whether or not a Director is independent;
- (g) Reviewing and deciding whether or not a Director who has multiple board representations on various companies is able to and has been adequately carrying out his/her duties as Director, having regard to the competing time commitments that are faced when serving on multiple boards and discharging his/her duties towards other principal commitments;
- (h) Deciding whether or not a Director of the Company is able to and has been adequately carrying out his/her duties as a Director; and
- (i) Developing a process for evaluation of the performance of the Board, the Board Committees and Directors and proposing objective performance criteria, as approved by the Board that allows comparison with its industry peers, and addresses how the Board has enhanced long-term shareholders' value.

4.2 The Board has established an NC which comprises four members, half of whom including the Chairman of the NC, are Independent Directors. The members of the NC, with the Lead Independent Director as Chairman, are as follows:

Sin Boon Ann	Chairman	Lead Independent Non-Executive Director
Dr Karl Lidgren	Member	Executive Director
John d'Abo	Member	Independent Non-Executive Director
Dr Mathias Lidgren	Member	Non-Independent Non-Executive Director

## CORPORATE GOVERNANCE REPORT

As part of the Company's progressive renewal of the Board, Dr Mathias Lidgren was appointed to the Board and to the NC on 4 May 2022, with the intention to take over the representation of the interests of Limea Ltd., the controlling shareholder of the Company, from Dr Karl Lidgren over time. As such, the composition of the NC during this transition period deviates from Provision 4.1 of the Code, which requires the majority of the NC members to be independent. Notwithstanding the foregoing, the Board is of the view that the Board has a formal and transparent process for the appointment and re-appointment of Directors to the Board, taking into account, among others, its key terms of reference, nomination process as disclosed herein.

4.3

The Company's process for the selection, nomination, appointment and re-appointment of directors to the Board, including the criteria used to identify and evaluate potential new directors and channels used in searching for appropriate candidates are detailed below.

### ***Board Nomination Process***

The Board has adopted the following nomination process for the Company in the last financial year for selecting and appointing new directors and re-electing incumbent directors:

#### ***Process for the Selection and Appointment of New Directors:***

1.	Determination of selection criteria	<ul style="list-style-type: none"> <li>The NC, in consultation with the Board, would identify the current needs of the Board in terms of skills, experience, knowledge and gender to complement and strengthen the Board and increase its diversity.</li> </ul>
2.	Search for suitable candidates	<ul style="list-style-type: none"> <li>The NC would consider candidates drawn from the contacts and networks of existing Directors and may approach relevant institutions such as the SID, professional organisations or business federations to source for a suitable candidate.</li> </ul>
3.	Assessment of shortlisted candidates	<ul style="list-style-type: none"> <li>The NC would meet and interview the shortlisted candidates to assess their suitability.</li> </ul>
4.	Appointment of Director	<ul style="list-style-type: none"> <li>The NC would recommend the selected candidate to the Board for consideration and approval.</li> <li>The Company will provide each newly appointed Director with a formal letter of appointment setting out the Director's duties and obligations.</li> </ul>

#### ***Process for the Re-election of Incumbent Directors:***

1.	Assessment of Director	<ul style="list-style-type: none"> <li>The NC would assess the performance of the Director in accordance with the performance criteria set by the Board.</li> <li>The NC would also consider the current needs of the Board.</li> </ul>
2.	Re-appointment of Director	<ul style="list-style-type: none"> <li>Subject to the NC's satisfactory assessment, the NC would recommend the proposed re-appointment of the Director to the Board for its consideration and approval.</li> </ul>

The Constitution requires that all Directors to retire from office once every three years. At each AGM, one-third of the Board (or, if their number is not a multiple of three, the number nearest to but not less than one-third) shall retire from office by rotation. A retiring Director is eligible for re-election by the shareholders at the AGM.

## CORPORATE GOVERNANCE REPORT

- 4.4 The NC has determined in 2022 that none of the Independent Directors has any relationships with the Company, its related corporations, its substantial shareholders or its officers, if any, which may affect their independence. Dr Christopher Atkinson is representing the Company as an Independent Director in the Group's subsidiaries, Lime Petroleum AS and Masirah Oil Ltd.
- 4.5 The NC ensures that new Directors are aware of their duties and obligations. The NC also decides if a Director is able to and has been adequately carrying out his or her duties as a Director of the Company.

### *Directors' Key Information*

Key information regarding the Directors, including their present and past three years' directorships in other listed companies and other principal commitments are set out below:

Name of Director	Position	Date of Initial Appointment	Date of Last Re-election / Re-appointment	Current Directorships in Other Listed Companies / Principal Commitments	Directorships in Other Listed Companies Over the Past Three Years
<b>Dan Broström</b>	Executive Chairman	11 January 2013	23 April 2021	Other Listed Companies: Nil  Principal Commitment: - Cathay (Venture) Pte Ltd - Havalina Pte Ltd - Xer Technologies Pte. Ltd.	NA
<b>Dr Karl Lidgren</b>	Executive Director	1 May 2013	29 April 2022	Other Listed Companies: Nil  Principal Commitment: - Cresta Group Ltd - Trace Atlantic Oil Ltd - Limea Ltd - Monarch Marine Holding Ltd - Orango Oil Ltd.	NA

## CORPORATE GOVERNANCE REPORT

Name of Director	Position	Date of Initial Appointment	Date of Last Re-election / Re-appointment	Current Directorships in Other Listed Companies Current / Principal Commitments	Directorships in Other Listed Companies Over the Past Three Years
<b>Sin Boon Ann</b>	Lead Independent Non-Executive Director	26 June 2013	23 April 2021	Other Listed Companies: - Healthway Medical Corporation Limited - OUE Limited - CSE Global Limited - TIH Limited - Sarine Technologies Ltd - The Trendlines Group Ltd  Principal Commitment: - Drew & Napier LLC	- HRnet Group Limited
<b>Dr Christopher Atkinson</b>	Independent Non-Executive Director	6 January 2015	29 April 2022	Other Listed Companies: - Far East Gold Ltd <sup>(2)</sup>  Principal Commitment: - Worldwide Petroleum Services Pte Ltd - Helios Aragon Pte Limited - Spice Islands Liquors Pte Limited	- Sonoro Energy Limited <sup>(1)</sup>

## CORPORATE GOVERNANCE REPORT

Name of Director	Position	Date of Initial Appointment	Date of Last Re-election / Re-appointment	Current Directorships in Other Listed Companies Current / Principal Commitments	Directorships in Other Listed Companies Over the Past Three Years
<b>Mae Heng</b>	Independent Non-Executive Director	4 May 2022	NA	Other Listed Companies: - HRnetGroup Limited - Chuan Hup Holdings Limited - Grand Venture Technology Limited - Ossia International Limited - Novo Tellus Alpha Acquisition - Apex Healthcare Berhad <sup>(5)</sup>  Principal Commitment: - Drew & Lee Investment (Private) Limited - Drew & Lee Holdings (Private) Limited - Drew & Lee Land Pte. Ltd.	NA



## CORPORATE GOVERNANCE REPORT

Name of Director	Position	Date of Initial Appointment	Date of Last Re-election / Re-appointment	Current Directorships in Other Listed Companies Current / Principal Commitments	Directorships in Other Listed Companies Over the Past Three Years
<b>John d'Abo</b>	Independent Non-Executive Director	4 May 2022	NA	Other Listed Companies: Nil  Principal Commitment: - Erland Advisors Ltd	NA
<b>Dr Mathias Lidgren</b>	Non-Independent Non-Executive Director	4 May 2022	NA	Other Listed Companies: Nil  Principal Commitment: - Moroxite Holding Pte. Ltd. - Propatria AB - Rotationsplast I Munka-Ljungby AB - Caithness Fastighets AB - Forvaltningsaktiebolaget Maple - Trolleholms Slott AB - Captiosus AB - Strominnate Therapeutics AB - Moroxite T - Medical Doctor - Postdoctoral Researcher - Moroxite T AB	NA

<sup>(1)</sup> Listed on TSX Venture Exchange <sup>(2)</sup> Listed on Australian Stock Exchange <sup>(3)</sup> Listed on Bursa Malaysia  
NA – Not Applicable

“Principal Commitments” as defined in the Code include all commitments which involve significant time commitment such as full time occupation, consultancy work, committee work, non-listed company board representations and directorships and involvement in non-profit organisations. Where a director sits on the boards of non-active related corporations, those appointments should not normally be considered principal commitments.

Further information on the Directors is set out on pages 10 to 13 of this Annual Report.

## CORPORATE GOVERNANCE REPORT

### ***Multiple Directorships***

The Board had previously capped the maximum number of listed company board representations each Director may hold to seven, to ensure that the Directors have sufficient time and attention to adequately perform their role. During the Board Meeting held on 26 February 2021, the NC opined that the effectiveness of each Director was best evaluated and determined by assessing his/her contributions and ability to devote sufficient time and attention to the Company's affairs and his/her acts in the interests of the Company. The Board agreed that representation on the board of directors of several listed companies was no longer a matter of concern to the Board. Hence, there was no need to set a numerical limit to the number of board memberships in listed companies that each Director might hold during his or her term of office.

The NC does not wish to omit from consideration outstanding individuals who, despite the demands on their time, have the capacity to participate and contribute as members of the Board.

The considerations in assessing the capacity of Directors include the following:

- Expected and/or competing time commitments of Directors;
- Geographical location of Directors;
- Size and composition of the Board; and
- Nature and scope of the Group's operations and size.

The NC takes into consideration the following measures and evaluation tools in its assessment of competing time commitments of Directors:

- Declarations by individual Directors of their other listed company board directorships and principal commitments;
- Annual confirmations by each Director on his/her ability to devote sufficient time and attention to the Company's affairs, having regard to his/her other commitments; and
- Assessment of the individual Directors' performance based on the criteria set out in Principle 5 of this report.

The NC has reviewed the time spent and attention given by each of the Directors to the Company's affairs, taking into account the multiple directorships and other principal commitments of each of the Directors (if any), and is satisfied that all Directors have discharged their duties adequately in FY2022.

### ***Alternate Directors***

The Company does not have any alternate directors on its Board currently. Alternate directors may be appointed as and when the Board deems necessary. Circumstances which warrant such appointments may include health and age related concerns as well as Management succession plans.

## CORPORATE GOVERNANCE REPORT

### ***Re-election of Directors***

Pursuant to the Company's Constitution, Mr Dan Broström and Mr Sin Boon Ann will retire by rotation as Director of the Company at the forthcoming AGM.

The NC has recommended to the Board that Mr Dan Broström and Mr Sin Boon Ann be re-elected at the forthcoming AGM.

Mr Dan Broström will, upon re-election as a Director, remain as Executive Chairman of the Company. Further information on Mr Dan Broström can be found on page 10 of the Annual Report.

Sin Boon Ann will, upon re-election as a Director, remain as the Lead Independent Non-Executive Director of the Company, the Chairman of the NC and the RC respectively, and a member of the AC. Further information on Sin Boon Ann can be found on page 11 of the Annual Report.

The Constitution further provides that any Director appointed to fill a casual vacancy or as an additional Director shall hold office only until the next AGM of the Company and shall then be eligible for re-election, but shall not be taken into account in determining the number of Directors who are to retire by rotation at such meeting.

The NC has recommended to the Board that Ms Mae Heng, Mr John d'Abo and Dr Mathias Lidgren, who are due to retire pursuant to the aforesaid provision, be re-elected at the forthcoming AGM.

Ms Mae Heng will, upon re-election as a Director, remain as an Independent Non-Executive Director of the Company and chairperson of the AC. Further information on Ms Mae Heng can be found on page 12 of the Annual Report.

Mr John d'Abo will, upon re-election as a Director, remain as an Independent Non-Executive Director of the Company and member of the AC and the NC. Further information on Mr John d'Abo can be found on page 12 of the Annual Report.

Dr Mathias Lidgren will, upon re-election as a Director, remain as a Non-Independent Non-Executive Director of the Company and member of the NC. Further information on Dr Mathias Lidgren can be found on page 13 of the Annual Report.

Each member of the NC has abstained from voting on any resolutions and making recommendation and/ or participating in respect of matters in which he has an interest.

### **Board Performance**

***Principle 5*** ***The Board undertakes formal annual assessment of its effectiveness as a whole, and that of each of its board committees and individual directors.***

#### 5.1 ***Performance Criteria***

The Board has established processes including taking into consideration the attendance record at the meetings of the Board and the Board Committees for monitoring and evaluating the performance of the Board as a whole and effectiveness and contribution of individual directors. At the same time, the processes also identify weaker areas where improvements can be made. The Board and individual directors can direct more effort in those areas for achieving better performance of the Board and better effectiveness of individual directors.

## CORPORATE GOVERNANCE REPORT

The NC has been tasked to evaluate the Board's performance covering areas that include, *inter alia*, size and composition of the Board, Board's access to information, Board processes, strategic planning and accountability.

The NC shall also review the overall performance of the Board in terms of its role and responsibilities and the conduct of its affairs as a whole.

The review of the performance of the Board is conducted by the NC annually. The review of the performance of each Director is also conducted at least annually and when the individual Director is due for re-election.

5.2 For FY2022, the review process was as follows:

1. All Directors individually completed a board evaluation questionnaire on the effectiveness of the Board based on criteria disclosed;
2. The Company Secretary collated and submitted the questionnaire results to the NC Chairman in the form of a report;
3. The NC discussed the report and concluded the performance results during the NC meeting; and
4. Each individual Director was also requested to send a duly completed confidential individual director self-assessment checklist to the NC chairman for review.

All NC members have abstained from the voting or review process of any matters in connection with the assessment of their individual performance.

The assessment criteria include, *inter alia*, Director's attendance, commitment of time, candour, participation, knowledge and abilities, teamwork, and overall effectiveness.

The NC would review the aforementioned criteria on a periodic basis to ensure that the criteria is able to provide an accurate and effective performance assessment taking into consideration industry standards and the economic climate with the objective to enhance long term shareholders value, and thereafter propose amendments if any, to the Board for approval. There has been no change in assessment criteria for FY2022 as the assessment criteria for the financial year ended 31 December 2021 was considered adequate for the aforementioned assessment.

The NC, having reviewed the overall performance of the Board in terms of its role and responsibilities and the conduct of its affairs as a whole, is of the view that the performance of the Board has been satisfactory in FY2022 and that the Board has met its performance objectives in FY2022. The evaluation process of the overall performance of the Board was conducted without an external facilitator in FY2022.

# CORPORATE GOVERNANCE REPORT

## REMUNERATION MATTERS

### Procedures for Developing Remuneration Policies

**Principle 6** *The Board has a formal and transparent procedure for developing policies on director and executive remuneration, and for fixing the remuneration packages of individual directors and key management personnel. No director is involved in deciding his or her own remuneration.*

6.1

### *Remuneration Committee*

To effect the best corporate governance, the Company has established an RC. The RC recommends to the Board a framework of remuneration for the Directors and key management personnel, and determines specific remuneration packages for each Director, as well as for key management personnel. The recommendations will be submitted for endorsement by the Board.

All aspects of remuneration, including but not limited to directors' fees, salaries, allowances, bonuses and benefits in kind, will be covered by the RC. The RC will also review annually the remuneration of employees who are immediate family members of a Director, CEO or substantial shareholder of the Company, to ensure that their remuneration packages are in line with staff remuneration guidelines and commensurate with their respective job scopes and level of responsibilities. The RC will also review and recommend to the Board any bonuses, pay increases and/or promotions for employees who are immediate family members of a Director, CEO and substantial shareholder. Each RC member will abstain from participating in the deliberations of and voting on any resolution in respect of his/her remuneration package or that of employees related to him/her.

The RC is guided by key terms of reference as follows:

- (a) Review and recommend to the Board a general framework of remuneration and specific remuneration packages for each Director and key management personnel;
- (b) Review and recommend to the Board the service contracts of Executive Directors and key management personnel and ensure that such service contracts are fair and not excessively long or with onerous renewal/termination clauses; and
- (c) In respect of long-term incentive schemes (if any) including share schemes as may be implemented, to consider whether Directors should be eligible for benefits under such long-term incentive schemes.

## CORPORATE GOVERNANCE REPORT

6.2 The RC comprises three members, of which a majority, including the chairman of the RC, are independent:

Sin Boon Ann	Chairman	Lead Independent Non-Executive Director
Dan Broström	Member	Executive Chairman
John d'Abo	Member	Independent Non-Executive Director

The RC does not comprise solely of Non-Executive Directors following the appointment of Mr Dan Broström, the Executive Chairman, as a member of the RC. Taking into account that the Executive Chairman would be able to provide relevant input and guidance to the RC, given his familiarity with the Group's activities as well as industry and market practices (including remuneration packages which are in line with the current market standards and commensurate with the respective job scope and responsibilities of executives) in jurisdictions where the Group operates, the NC had recommended his appointment to the Board. The Board opined that as the RC continued to have majority representation of independent directors, the independent directors collectively, would have the decisive vote in relation to executive remuneration matters. Furthermore, retaining an RC member who is in an executive position will not lead to a conflict of interest or impede the independence of the RC as no Director or member of the RC is allowed to participate in the deliberation, and has to abstain from voting on any resolution, relating to his own remuneration or that of employees related to him. Based on the foregoing, the Board had approved Mr Dan Broström's appointment as a member of the RC.

6.3 The RC considers all aspects of remuneration, including director's fees, salaries, allowances, bonuses, options, share-based incentives and awards, benefits in kind and termination terms, to ensure that they are fair and avoid rewarding poor performance. The RC also reviews the Company's obligations arising in the event of termination of the Executive Directors' and key management personnel's contracts of service, to ensure that such contracts of service contain fair and reasonable termination clauses which are not overly generous.

### 6.4 **Remuneration Consultant**

The RC may from time to time, where necessary or required, seek advice from external consultants in framing the remuneration policy and determining the level and mix of remuneration for Directors and Management, so that the Group remains competitive in this regard. No external remuneration consultant was engaged for FY2022.

## Level and Mix of Remuneration

**Principle 7** *The level and structure of remuneration of the Board and key management personnel are appropriate and proportionate to the sustained performance and value creation of the company, taking into account the strategic objectives of the company.*

### 7.1 **Remuneration Structure**

In setting remuneration packages, the RC will take into consideration the pay and employment conditions within the industry and in comparable companies. The RC also seeks to ensure that the structure of remuneration packages for the Executive Chairman, the Executive Director and key management personnel are appropriate in linking rewards with performance and are aligned with the interests of shareholders and promote the long-term success of the Group.

## CORPORATE GOVERNANCE REPORT

7.2 The remuneration of the Independent Non-Executive Directors and the Non-Independent Non-Executive Director are also reviewed by the RC to ensure that the remuneration is commensurate with the contribution, taking into account factors such as effort, time spent and responsibilities of the respective Non-Executive Directors.

### ***Performance Criteria for Remuneration***

The remuneration received by the Executive Directors and key management personnel takes into consideration his or her individual performance and contribution towards the overall performance of the Group for FY2022. Their remuneration is made up of fixed and variable compensation. The fixed compensation consists of an annual base salary, fixed allowance and annual wage supplement. The variable compensation is determined based on the level of achievement of corporate performance objectives.

The Company's Executive Directors and key management personnel have been assessed against performance targets set based on the average of the Company's closing market prices of shares over a consecutive period of five market days in which transaction of the shares were to be recorded and achieved over a set time period.

The remuneration of the Executive Chairman includes a per hour rate with a cap and a variable performance related bonus, which is designed to align the interests of the Executive Chairman with those of shareholders.

The Independent and Non-Independent Non-Executive Directors receive Directors' fees based on their responsibilities, effort and time spent. The Directors' fees are recommended by the RC and endorsed by the Board for approval by the shareholders of the Company at the AGM.

### ***Contractual Provisions***

The present Service Agreements do not include contractual provisions to allow the Company to reclaim incentive components of remuneration from Executive Directors and key management personnel in exceptional circumstances of misstatement of financial results, or of misconduct resulting in financial loss to the Company. The Company will consider to include this provision for future new service agreements and renewal of service agreements, if appropriate. However, the Company has included in the terms of the Rex International Performance Share Plan, allowance for the Company to cancel the share awards before the date of the vesting of the awards, in the event of misconduct, at its discretion. The Company has also included in the terms of the Rex International Employee Share Option Scheme, to allow for the share option committee to cancel unexercised options in the event of misconduct, at its discretion.

7.3 The Company believes that the remuneration for its Directors is appropriate to attract, retain and motivate them to provide good stewardship of the Company and key management personnel to successfully manage the Company for the long term.

## CORPORATE GOVERNANCE REPORT

### Disclosure on Remuneration

**Principle 8** *The company is transparent on its remuneration policies, level and mix of remuneration, the procedure for setting remuneration, and the relationships between remuneration, performance and value creation.*

#### 8.1 *Directors' Remuneration*

8.1 (a) The Company's remuneration policy is one that seeks to attract, retain and motivate talent to achieve the Company's business vision and create sustainable value for its stakeholders. The policy articulates to staff the link that total compensation has to the achievement of organisational and individual performance objectives, and benchmarked against relevant and comparative compensation in the market.

The breakdown for the remuneration of the Non-Executive Directors for FY2022 is as follows:

Name of Non-Executive Director	Directors' Fees S\$	Bonus S\$	Others <sup>(1)</sup> S\$	Total S\$
Muhammad Sameer Yousuf Khan <sup>(4)</sup>	46,041	180,000	8,989	235,030
Sin Boon Ann	135,588	315,000 <sup>(2)</sup>	–	450,588
Dr Christopher Atkinson	58,108	315,000 <sup>(2)</sup>	82,736	455,844
Dr Mathias Lidgren <sup>(5)</sup>	44,948	135,000 <sup>(3)</sup>	–	179,948
Mae Heng <sup>(5)</sup>	64,211	135,000 <sup>(3)</sup>	–	199,211
John d'Abo <sup>(5)</sup>	54,580	135,000 <sup>(3)</sup>	–	189,580

<sup>(1)</sup> Others include fees paid/ payable for directorship in subsidiaries.

<sup>(2)</sup> Out of S\$315,000 of performance bonus paid/ payable to each of Mr Sin Boon Ann and Dr Christopher Atkinson, S\$135,000 is subject to shareholders' approval at the upcoming annual general meeting.

<sup>(3)</sup> S\$135,000 of performance bonus payable to each of Dr Mathias Lidgren, Ms Mae Heng and Mr John d'Abo, is subject to shareholders' approval at the upcoming annual general meeting.

<sup>(4)</sup> Retired on 29 April 2022.

<sup>(5)</sup> Appointed on 4 May 2022.

There were no termination, retirement or post-employment benefits (excluding CPF) granted to the Non-Executive Directors in FY2022.

Directors have remuneration packages consisting of basic retainer fees as directors and fees for directorship in subsidiaries, with additional fees for attendance and serving on Board Committees.

Remuneration to Executive Directors includes in part the aforementioned components of directorship, and in part compensation to reflect the additional responsibilities to execute strategic plans of the Group.



## CORPORATE GOVERNANCE REPORT

The breakdown of directors' fees for FY2022 paid/ payable to the respective Directors of the Company is as follows:

Name of Director	Board Fee S\$	AC S\$	RC S\$	NC S\$	Others S\$	Total S\$
Dan Broström	116,217	19,370	14,527	-	-	150,114
Dr Karl Lidgren	58,108	-	-	9,685	-	67,793
Muhammad Sameer <sup>(2)</sup>						
Yousuf Khan	22,100	14,733	5,525	3,683	-	46,041
Sin Boon Ann	58,108	19,370	29,055	19,370	9,685 <sup>(1)</sup>	135,588
Dr Christopher Atkinson	58,108	-	-	-	-	58,108
Dr Mathias Lidgren <sup>(3)</sup>	38,527	-	-	6,421	-	44,948
Mae Heng <sup>(3)</sup>	38,527	25,684	-	-	-	64,211
John d'Abo <sup>(3)</sup>	38,527	-	9,632	6,421	-	54,580
	428,222	79,157	58,739	45,580	9,685	621,383

<sup>(1)</sup> Remuneration for Lead Independent Director.

<sup>(2)</sup> Retired on 29 April 2022.

<sup>(3)</sup> Appointed on 4 May 2022.

### ***Executive Directors, CEO and Key Management Personnel's Remuneration***

The Board is of the view that full disclosure of the exact details of the remuneration of each of the Executive Directors and CEO is not in the best interests of the Company or its shareholders. In arriving at its decision, the Board had taken into consideration, *inter alia*, the commercial sensitivity and confidential nature of remuneration matters, the relative size of the Group, the competitive business environment in which the Group operates, the importance of ensuring stability and continuity of business operations with a competent and experienced management team in place and the negative impact which such disclosure may have on the Group in attracting and retaining talent for the Company on a long-term basis.

Notwithstanding the non-disclosure of the exact remuneration of the Executive Directors and the CEO of the Company (which deviates from the Provision 8.1(a) of the Code), the Board is of the view that the intent of Principle 8 on transparency has been adhered to, given that a high level of transparency on remuneration matters including procedures for developing remuneration policies and level and mix of remuneration have been disclosed in this corporate governance report.

## CORPORATE GOVERNANCE REPORT

- 8.1 (b) The breakdown for the remuneration of the Company's Executive Directors, the CEO and key management personnel for FY2022 is disclosed in bands of S\$250,000 as follows:

Name of Executive Director/ CEO/ Key Management Personnel	Salary %	Bonus %	Benefits %	Directors' Fees %	Others <sup>(4)</sup> %	Total %
<b>S\$4,000,001 to S\$4,250,000</b>						
Måns Lidgren <sup>(1)</sup>	31	45	24	-	-	100
<b>S\$3,500,001 to S\$3,750,000</b>						
Per Lind	21	74	2	-	3	100
<b>S\$2,750,001 to S\$3,000,000</b>						
Dan Broström <sup>(2)</sup>	18	75	1	5	1	100
<b>S\$1,500,001 to S\$1,750,000</b>						
Dr Karl Lidgren <sup>(2)</sup>	29	64	1	4	2	100
<b>S\$500,001 to S\$750,000</b>						
Svein Kjellesvik <sup>(3)</sup>	100	-	-	-	-	100
Kristofer Skantze <sup>(3)</sup>	57	43	-	-	-	100
<b>S\$250,001 to S\$500,000</b>						
Mok Lai Siong	83	16	1	-	-	100

<sup>(1)</sup> Mr Måns Lidgren is the CEO of the Company and he does not sit on the board of Directors. His remuneration is paid indirectly from various Group companies.

<sup>(2)</sup> Dr Karl Lidgren and Dan Broström are the Executive Directors of the Company.

<sup>(3)</sup> Remuneration is paid indirectly from various Group companies.

<sup>(4)</sup> Others include fees paid/payable for directorship in subsidiaries.

For FY2022, there were four key management personnel in the Company, aside from the two Executive Directors and the CEO. The annual aggregate remuneration paid to the top four key management personnel of the Company for FY2022 was S\$5,229,264.

There were no termination, retirement or post-employment benefits (excluding CPF) granted to the Executive Directors, the CEO and the top four key management personnel in FY2022.

8.2

### ***Substantial Shareholder and Immediate Family Members of a Director or the CEO or Substantial Shareholder***

The details of the remuneration to Dr Karl Lidgren (Executive Director and a substantial shareholder of the Company), Mr Svein Kjellesvik (a key management personnel of the Group and a substantial shareholder of the Company), Mr Måns Lidgren (CEO and son of Dr Karl Lidgren) and Dr Mathias Lidgren (son of Mr Hans Lidgren, a substantial shareholder of the Company) are disclosed in the table under Provision 8.1(a) and 8.1(b).

Mr Hans Lidgren, an executive of Rex Technology Investments Ltd, is a substantial shareholder of the Company, the brother of Executive Director, Dr Karl Lidgren, father of Dr Mathias Lidgren and uncle of Mr Måns Lidgren, the CEO. Mr Hans Lidgren's remuneration for FY2022 was in the band of S\$900,001 to S\$1,000,000.

## CORPORATE GOVERNANCE REPORT

Mrs Lina Berntsen, Chief Technology Officer, is the daughter of Mr Hans Lidgren, sister of Dr Mathias Lidgren, niece of Executive Director, Dr Karl Lidgren and cousin of Mr Måns Lidgren, the CEO. Mrs Lina Berntsen's remuneration for FY2022 was in the band of S\$200,001 to S\$300,000.

Mr Martin Lidgren, Technology Specialist at Equus Consulting AB, a wholly-owned subsidiary of Rex Technology Management Ltd, is the son of Executive Director, Dr Karl Lidgren, brother of Mr Måns Lidgren, the CEO, nephew of Hans Lidgren and cousin of Dr Mathias Lidgren. Mr Martin Lidgren's remuneration for FY2022 was in the band of S\$200,001 to S\$300,000.

Mr Magnus Lidgren, Technology Specialist at Equus Consulting AB, a wholly-owned subsidiary of Rex Technology Management Ltd, is the brother of Executive Director, Dr Karl Lidgren and Mr Hans Lidgren, and uncle of Dr Mathias Lidgren and Mr Måns Lidgren, the CEO. Mr Magnus Lidgren's remuneration for FY2022 was in the band of S\$200,001 to S\$300,000.

Mr Fredrik Broström, Business Development Manager, is the son of Executive Director, Mr Dan Broström. Mr Fredrik Broström's remuneration for FY2022 was in the band of S\$200,001 to S\$300,000.

Save for the aforementioned, there is no other employee of the Company who is a substantial shareholder of the Company or an immediate family member of a Director, the CEO or a substantial shareholder of the Company, whose remuneration exceeded S\$100,000 during FY2022.

8.3

### ***Employee Share Scheme***

#### ***Rex International Employee Share Option Scheme ("ESOS")***

The Company has an ESOS which was approved and adopted by the members of the Company at an EGM on 24 June 2013, and amended with shareholders' approval at an EGM of the Company on 3 March 2022. The ESOS is designed to reward valuable and outstanding employees or Non-Executive Directors (including Independent Directors), and incentivise them to continue contributing to the long-term growth and success of the Group.

The ESOS allows for participation by employees or Non-Executive Directors (including Independent Directors) of the Group who have attained the age of 21 years and above on or before the date of grant of the option, provided that none of them is a discharged bankrupt. Controlling shareholders and their associates are not eligible to participate in the ESOS.

The ESOS is administered by the RC in consultation with the CEO. Please refer to Provision 6.2 for the members of the RC. The total number of new shares over which options may be granted pursuant to the ESOS, when added to the number of shares issued and issuable in respect of all options granted under the ESOS and all awards granted under any other share option, share incentive, performance share or restricted share plan implemented by the Company and for the time being in force, shall not exceed 15 per cent of the number of all issued shares of the Company (excluding treasury shares), on the day preceding the date of the relevant grant.

## CORPORATE GOVERNANCE REPORT

Other salient information regarding the ESOS is set out below:

### ***Exercise Price of Options***

The exercise price of options shall be determined at the discretion of the RC on the date which the options are granted and may be set at:

- A price equal to the average of the last dealt prices for the Company's shares on SGX-ST over the five consecutive trading days immediately preceding the date that option was granted, as determined by the RC by reference to the daily official list or any other publication published by the SGX-ST, rounded to the nearest whole cent in the event of fractional prices (the "**Market Price**"); or
- A discount to the Market Price not exceeding 20 per cent of the Market Price (or such other percentage or amount as may be determined by the RC) in respect of options granted at the time of grant, provided that shareholders in general meeting have authorised, in a separate resolution, the making of offers and grants of options under the ESOS at a discount not exceeding the maximum discount as aforesaid.

For the options granted with exercise price set at Market Price, they can be exercised one year from the date of the grant and will expire five years from the date of the grant.

For the options granted with exercise price set at a discount to Market Price, they can be exercised two years from the date of the grant and will expire five years from the date of the grant.

### ***Duration of the ESOS***

The ESOS shall be in force for a maximum of 10 years from the date on which the ESOS was adopted. Upon obtaining the approval of shareholders by ordinary resolution in general meeting and of any relevant authorities which may be required, the ESOS may continue beyond 10 years from the date it was adopted. The ESOS will be expiring on 24 June 2023. The RC will constantly evaluate and assess the adoption of any new share-based compensation scheme or long-term incentive plan, with the aim of enhancing the link between rewards and corporate and individual performance.

No options were granted by the Company during FY2022. As at 31 December 2022, there are no options outstanding as all options granted have expired. Further details on the ESOS were set out in the Company's circular to shareholders dated 9 February 2022.

### ***Rex International Performance Share Plan ("Rex PSP")***

The Rex PSP (the "**Plan**") was adopted by the Company on 24 June 2013 and amended with shareholders' approval at EGMs of the Company on 30 April 2014, 28 April 2017 and 3 March 2022. The objective of the Plan is to promote higher performance goals and recognise the achievements of employees or Non-Executive Directors (including Independent Directors) ("**Participants**") by motivating and aligning their interests to the Group's pre-determined goals. The Plan is administered by the RC in consultation with the CEO. Please refer to Provision 6.2 for the members of RC. The Rex PSP will be expiring on 24 June 2023. The RC will constantly evaluate and assess the adoption of any new share-based compensation scheme or long-term incentive plan, with the aim of enhancing the link between rewards and corporate and individual performance.

## CORPORATE GOVERNANCE REPORT

The Plan contemplates the award of such number of fully-paid shares granted under the Rex PSP (“Awards”), free of charge, to Participants after certain pre-determined benchmarks have been met. Awards granted under the Plan may be time-based or performance-related. Performance targets set are based on short to medium-terms corporate objectives including market competitiveness, quality of returns, business growth and productivity growth. These performance targets may include targets set based on criteria such as shareholders’ return, return on equity and earnings per share.

The length of the vesting period in respect of the Awards of such number of fully-paid ordinary shares granted under the Plan will be determined on a case-by-case basis by the RC.

Details of the outstanding Awards granted as at 31 December 2022 are as follows:

Date of Grant of Awards	Number of Awards					Number of Holders
	At 1-Jan-22	Granted in FY2022	Lapsed/ Cancelled in FY2022	Vested in FY2022	At 31-Dec-22	
9-Mar-21	11,724,100 <sup>(1)</sup>	-	(11,724,100) <sup>(2)</sup>	-	-	-
8-Apr-22	-	11,724,100 <sup>(3)</sup>	(1,200,000) <sup>(4)</sup>	-	10,524,100	3
20-Oct-22	-	3,600,000 <sup>(3)</sup>	-	-	3,600,000	3
	<b>11,724,100</b>	<b>15,324,100</b>	<b>(12,924,100)</b>	<b>-</b>	<b>14,124,100</b>	<b>6</b>

<sup>(1)</sup> On 9 March 2021, the Company granted 11,724,100 Awards to certain directors of the Company. The number of Awards to be vested will range from 0% to 100%, subject to fulfilment of certain predetermined performance benchmarks and the satisfactory completion of time-based service condition.

If the Average Performance Market Price\* is S\$0.30 and above, 50% of the Awards shall be released after the vesting period. If the Average Performance Market Price is S\$0.45 and above, an additional 50% of the Awards shall be released. If the Average Performance Market Price is less than S\$0.30, none of the Awards shall be released unless otherwise determined by the committee administering the PSP.

<sup>(2)</sup> On 8 April 2022, 5,862,050 Awards previously granted had been cancelled (forthwith lapsed and to be of no value).

On 29 April 2022, 5,862,050 Awards previously granted had been cancelled (forthwith lapsed and to be of no value), subsequent to the approval of payment of additional remuneration to certain Directors at the conclusion of the annual general meeting held on 29 April 2022.

<sup>(3)</sup> On 8 April 2022 and 20 October 2022, the Company granted 11,724,100 and 3,600,000 Awards respectively to certain directors of the Company. The number of Awards to be vested will range from 0% to 100%, subject to fulfilment of certain predetermined performance benchmarks and the satisfactory completion of time-based service condition.

If the Average Performance Market Price\* is S\$0.45 and above, 50% of the number of shares in the Awards shall be released. If the Average Performance Market Price is S\$0.60 and above, an additional 50 per cent of the number of shares in the Awards shall be released. If the Average Performance Market Price is less than S\$0.45 and S\$0.60 in 2022 and 2023 respectively, a Key Performance Indicator-based incentive scheme (“**KPI-based Incentive Scheme**”) shall apply and the number of shares to be released under the Awards will range from 0% to 100%, subject to the fulfilment of the predetermined performance targets in the KPI-based Incentive Scheme. The committee administering the Rex PSP may also modify the release of the Awards in tranches at its own discretion, in accordance with the rules of the Rex PSP.

<sup>(4)</sup> On 29 April 2022, 1,200,000 Awards previously granted to a director had been cancelled (forthwith lapsed and to be of no value), subsequent to his retirement as Independent Non-Executive Director.

## CORPORATE GOVERNANCE REPORT

On 13 March 2023, all 14,124,100 outstanding Awards as at 31 December 2022 were cancelled (forthwith lapsed and to be of no value).

\* **Average Performance Market Price** refers to the average of Company's closing market prices of Shares over a consecutive period of five (5) market days in which transactions in the Shares were recorded, at any time within a two-year period from the date of Awards.

Details of the Awards granted to participants who are directors and controlling shareholders or associates of the controlling shareholders and participants who received more than 5% of the total grants since the commencement of Rex PSP are as follows:

Name of participant	Awards granted in FY2022	Net aggregate Awards granted since commencement of Rex PSP to 31 Dec 2022 <sup>(1)</sup>	Awards released in FY2022	Aggregate Awards released since commencement of Rex PSP to 31 Dec 2022 <sup>(1)</sup>	Aggregate Awards outstanding and which have not been released as at 31 Dec 2022
<b>Directors</b>					
Dan Broström <sup>(1)</sup>	8,124,100	14,217,175	–	(6,093,075)	8,124,100
Sin Boon Ann <sup>(2)</sup>	1,200,000	2,100,000	–	(900,000)	1,200,000
Dr Christopher Atkinson <sup>(3)</sup>	1,200,000	1,620,000	–	(420,000)	1,200,000
Dr Mathias Lidgren <sup>(4)</sup>	1,200,000	1,200,000	–	–	1,200,000
Mae Heng <sup>(5)</sup>	1,200,000	1,200,000	–	–	1,200,000
John d'Abo <sup>(6)</sup>	1,200,000	1,200,000	–	–	1,200,000
<b>Controlling shareholders or associates of the controlling shareholders</b>					
Måns Lidgren <sup>(7)</sup>	–	14,241,464	–	(14,241,464)	–
<b>Participants who received 5% or more of the total grants available</b>					
Per Lind	–	11,017,691	–	(11,017,691)	–
Kristofer Skantze	–	7,439,504	–	(7,439,504)	–
Mok Lai Siong	–	6,070,952	–	(6,070,952)	–

<sup>(1)</sup> Aggregate Awards granted less aggregate Awards granted that have since been lapsed/ cancelled

<sup>(2)</sup> Including new shares issued and allotted, and existing shares purchased

<sup>(1)</sup> Mr Dan Broström is the Chairman and Executive Director of the Company.

<sup>(2)</sup> Mr Sin Boon Ann is an Independent Non-Executive Director of the Company.

<sup>(3)</sup> Dr Christopher Atkinson is an Independent Non-Executive Director of the Company.

<sup>(4)</sup> Dr Mathias Lidgren is a Non-Independent Non-Executive Director of the Company.

<sup>(5)</sup> Ms Mae Heng is an Independent Non-Executive Director of the Company.

<sup>(6)</sup> Mr John d'Abo is an Independent Non-Executive Director of the Company.

<sup>(7)</sup> Mr Måns Lidgren (the CEO of the Company) is an associate of Dr Karl Lidgren, Executive Director and a controlling shareholder of the Company.

Save as disclosed in the table above, no other director, controlling shareholder or associates of controlling shareholders received any shares under the Rex PSP since the commencement of the Rex PSP.

## CORPORATE GOVERNANCE REPORT

No Awards have been granted to any controlling shareholders or associates of the controlling shareholders or any directors and employees of the Company's parent company and its subsidiaries in FY2022.

The vesting and release of the Awards granted to eligible participants (including Mr Måns Lidgren) under the Rex PSP are based on pre-determined performance goals and conditional on the satisfactory completion of time-based service conditions.

Further details on the Rex PSP were set out in the Company's circular to shareholders dated 9 February 2022.

### ACCOUNTABILITY AND AUDIT

#### Risk Management and Internal Controls

**Principle 9** *The Board is responsible for the governance of risk and ensures that Management maintains a sound system of risk management and internal controls, to safeguard the interests of the company and its shareholders.*

9.1 The Board, with the assistance from the AC and the Risk Management Committee ("**RMC**"), is responsible for risk governance and ensuring that Management maintains a sound system of risk management and internal controls to safeguard the shareholders' interests and the Company's assets. The Board appreciates that risk management is an on-going process in which Management continuously participates to evaluate, monitor and report to the Board and the AC on significant risks. The RMC was formed in October 2013. The current RMC consists of the following members: Ms Mae Heng (Independent Non-Executive Director and Chairman of the AC), Mr Per Lind (Chief Financial Officer ("**CFO**")), Mr Svein Kjeilesvik (COO) and Ms Lixian Wu (Financial Controller).

From FY2013 to FY2018, the Company developed and established a Board Assurance Framework ("**BAF**"), with the assistance of an independent third party, KPMG Services Pte. Ltd. The BAF, which includes an enterprise risk management framework, was utilised by the Company to identify and manage the significant and material risks it faces, the potential impact and likelihood of those risks occurring, the control effectiveness and action plans being taken to mitigate those risks.

The risk review in FY2022 was done in-house. The RMC has considered in detail the most material risks for the Company which include strategic, financial, operational, compliance, fraud and corruption, litigation and cyber security risks; and has put in place risk controls, action plans and key risk indicators to mitigate these risks, the details of which contain market sensitive information and hence are kept confidential.

The Company has established risk appetite statements with tolerance limits to monitor shifts in its significant risks and to proactively manage them within acceptable levels. These appetite statements have been reviewed and approved by the Board and are monitored on a yearly basis.

In FY2022, the Company appointed an independent third party, RSM Risk Advisory Pte Ltd ("**RSM**"), as the Internal Auditors ("**IA**") on a project basis, to perform internal audit reviews and highlight all significant matters to Management and the AC on an annual basis on various selected internal control areas.

## CORPORATE GOVERNANCE REPORT

9.2

### ***Adequacy and Effectiveness of Internal Controls***

The Board is of the view that the Company's internal controls (including financial, operational, compliance and information technology controls) and risk management systems were adequate and effective for FY2022.

The bases for the Board's view are as follows:

- (a) Assurance has been received from the CEO and the CFO;
- (b) An internal audit has been done by the IA and significant matters highlighted to the AC and Management were appropriately addressed;
- (c) Management regularly evaluates, monitors and reports to the AC and the RMC on material risks;
- (d) Discussions were held between the AC and auditors in the absence of Management to review and address any potential concerns;
- (e) An enterprise risk management framework was in place to identify, manage and mitigate significant risks; and
- (f) Risk appetite statements with tolerance limits have been approved by the Board to contain risks within acceptable levels and are monitored on a yearly basis.

The AC is responsible for making the necessary recommendations to the Board regarding the adequacy and effectiveness of the risk management and internal control systems of the Company. In this regard, the AC is assisted by the enterprise risk reports from the RMC.

For FY2022, the Board has obtained the following assurance:

- (a) From the CEO and the CFO that the financial records have been properly maintained and the financial statements give a true and fair view of the Company's operations and finances; and
- (b) From the CEO and other key management personnel who are responsible, regarding the adequacy and effectiveness of the Company's risk management and internal control systems.

The Board has relied on the independent auditors' report as set out in this Annual Report as assurance that the consolidated financial statements give a true and fair view of the Group's financial position and performance.

In relation to sustainability, the Group, as a young company, aspires to do good in the communities it operates in, be it to have minimal impact on the environment in its operations, or in helping the underprivileged. Please refer to the Sustainability section on pages 52 to 89 of this Annual Report for more details.



# CORPORATE GOVERNANCE REPORT

## Audit Committee

### **Principle 10** *The Board has an Audit Committee (“AC”) which discharges its duties objectively.*

10.1

The AC is guided by the following key terms of reference:

- (a) Reviewing the significant financial reporting issues and judgements, so as to ensure the integrity of the financial statements of the Company and any announcements relating to the Company’s financial performance. Where the external auditors (“EA”), in their review or audit of the Company’s year-end financial statements, raise any significant issues (for example, significant adjustments) which have a material impact on the interim financial statements or financial updates previously announced by the Company, the AC is to bring this to the Board’s attention immediately;
- (b) Advise the Board if changes are needed to improve the quality of future interim financial statements or financial updates;
- (c) Reviewing at least annually the adequacy and effectiveness of the Company’s internal controls and risk management systems;
- (d) Reviewing the assurance from the CEO and the CFO on the financial records and financial statements;
- (e) Making recommendations to the Board on: (i) the proposals to the shareholders on the appointment and removal of the EA; and (ii) the remuneration and terms of engagement of the EA;
- (f) Reviewing the adequacy, effectiveness, independence, scope and results of the Company’s IA and EA, the audit plans, scope of work, their evaluation of the system of internal accounting controls, their management letter and Management’s response, and results of the audits compiled by the IA and EA;
- (g) Reviewing the policy and arrangements for concerns about possible improprieties in financial reporting or other matters to be safely raised, independently investigated and appropriately followed up on. The Company publicly discloses, and clearly communicates to employees, the existence of a whistle-blowing policy and procedures for raising such concerns;
- (h) Assisting the Board of Directors in the discharge of its responsibilities on financial reporting matters;
- (i) Reviewing financial statements and results announcements before submission to the Board of Directors for approval, focusing in particular, on changes in accounting policies and practices, major risk areas, significant adjustments resulting from the audit, the going concern statement, compliance with financial reporting standards as well as compliance with the Listing Rules and any other statutory/regulatory requirements. Quarterly financial statements are made, but announcements are only made for half-year and annual results. Announcements on use of funds/ cash by mineral, oil and gas companies are made quarterly;
- (j) Reviewing the effectiveness and adequacy of the Group’s internal control and procedures, including accounting and financial controls and procedures and ensure co-ordination between the IA, the EA and Management, reviewing the assistance given by Management to the auditors, and discussing problems and concerns, if any, arising from the interim and final audits, and any matters which the auditors may wish to discuss (in the absence of Management where necessary);

## CORPORATE GOVERNANCE REPORT

- (k) Reviewing and discussing with the EA and the IA any suspected fraud or irregularity, or suspected infringement of any relevant laws, rules or regulations, which has or is likely to have a material impact on the Group's operating results or financial position, and Management's response;
- (l) Making recommendations to the Board of Directors on the proposals to the shareholders on the appointment, re-appointment and removal of the EA, and approving the remuneration and terms of engagement of the EA;
- (m) Assessing the quality of the work carried out by the EAs, and the basis of such assessment;
- (n) Reviewing and reporting to the Board of Directors at least annually the adequacy and effectiveness of the Group's material internal controls including financial, operation, compliance and information technology controls via reviews carried out by the IA;
- (o) Reviewing and approving transactions falling within the scope of Chapters 9 and 10 of the Listing Rules (if any);
- (p) Reviewing any potential conflicts of interest;
- (q) Reviewing and approving all hedging policies and instruments (if any) to be implemented by the Group;
- (r) Undertaking such other reviews and projects as may be requested by the Board of Directors and reporting to the Board of Directors its findings from time to time on matters arising and requiring the attention of the AC;
- (s) Reviewing and establishing procedures for receipt, retention and treatment of complaints received by the Group, *inter alia*, criminal offences involving the Group or its employees, questionable accounting, auditing, business, safety or other matters that impact negatively on the Group, including the oversight of whistleblowing; and
- (t) Generally undertaking such other functions and duties as may be required by statute or the Listing Rules, and by such amendments made thereto from time to time.

### **Authority of the AC**

Apart from the duties listed above, the AC shall commission and review the findings of internal investigations into matters where there is any suspected fraud or irregularity, or failure of internal controls or infringement of any Singapore law, rule or regulation which has or is likely to have a material impact on the Group's operating results and/or financial position. Each member of the AC will abstain from participating in the deliberations of and voting in respect of matters in which he is interested.

The AC has the power to conduct or authorise investigations into any matters within the AC's terms of reference. The AC has full access to and co-operation of the Management and has full discretion to invite any Director or executive officer to attend its meetings, and has been given reasonable resources to enable it to discharge its functions.

The AC is authorised to obtain independent professional advice as it deems necessary in the discharge of its responsibilities. Such expenses are to be borne by the Company.

#### 10.2

The Company has established the AC comprising the following three members, the majority of whom, including the Chairman of the AC, are independent:

Mae Heng	Chairman	Independent Non-Executive Director
Dan Broström	Member	Executive Chairman
Sin Boon Ann	Member	Lead Independent Non-Executive Director

## CORPORATE GOVERNANCE REPORT

However, not all of the members of the AC are Non-Executive Directors. Mr Dan Broström, the Executive Chairman, is a member of the AC. Taking into account that he would be able to provide relevant input and guidance to the AC, given his familiarity with the Group's activities as well as industry and market practices in jurisdictions where the Group operates, the NC had recommended his appointment to the Board. The Board had then approved his appointment as a member of the AC. Further, the Board is of the opinion that the AC continues to have majority representation of independent directors, and the independent directors collectively, would have the decisive vote in relation to proposals made by the Management. The AC (excluding Mr Dan Broström) meets with the external and internal auditors without the presence of Management at least once a year, to, *inter alia*, ascertain if there are any material weaknesses or control deficiency in the Group's financial reporting and operational systems. Mr Dan Broström, being an Executive Director, has been excluded from the aforesaid meetings to ensure that the AC remains a platform for external and internal auditors to provide their independent opinions without the influence of Management. This arrangement is essential to ensure that the presence of an Executive Director on the AC will not lead to any conflict of interest or impede the independence of the AC.

The remaining members of the AC are Independent Non-Executive Directors who do not have any management and business relationships with the Company or any substantial shareholder of the Company.

At least two members, including the AC Chairman, have recent and relevant accounting or related financial management expertise or experience.

Ms Mae Heng, the Chairperson of the AC, has over 16 years of experience working at Ernst & Young Singapore. She is an Independent Non-Executive Director of Novo Tellus Alpha Acquisition, Grand Venture Technology Limited, Chuan Hup Holdings Limited, HRnetGroup Limited, Ossia International Limited and Apex Healthcare Berhad, and is the chairperson or a member of these companies' various board committees. Ms Heng also holds directorships in her family-owned investment holding companies. She was also the former Audit Committee Chairperson of an SGX-listed real estate developer, as well as an online travel company. Mr Sin Boon Ann, a member of the AC, was with Drew & Napier LLC from 1992 to March 2018; his last appointment being Deputy Managing Director, Corporate and Finance Department and Co-head of the Capital Markets Practice, before his retirement. Mr Sin is currently a consultant at Drew & Napier LLC.

- 10.3 None of the AC members were previous partners or directors of the Company's existing external auditing firm within the previous 24 months and none of the AC members hold any financial interest in the external auditing firm or auditing corporation.
- 10.4 The primary reporting line of the internal audit function is to the AC, which also decides on the appointment, termination and remuneration of the head of the internal audit function. The internal audit function has unfettered access to all the Company's documents, records, properties and personnel, including the AC, and has appropriate standing within the Company.

## CORPORATE GOVERNANCE REPORT

### *Qualifications of the AC*

The Board is of the view that the AC chairman and members are appropriately qualified, with the necessary accounting, financial advisory, business management, corporate and finance, investment and corporate legal expertise and experience to discharge the AC's functions. The AC chairperson, having more than 16 years of experience in the fields of audit, accounting, business and financial advisory, and chairmanship or membership of various board committees of several other listed companies in Singapore, is well qualified to chair the AC.

10.5

### *Meeting between the AC and Auditors*

The AC (excluding Executive Chairman Mr Dan Broström) meets with the external and internal auditors without the presence of Management at least once a year, to, *inter alia*, ascertain independently, if there are any material weaknesses or control deficiency in the Group's financial reporting and operational systems. The AC has separately met with the IA and the EA once in the absence of Management in relation to FY2022.

### *Independence of External Auditor*

The AC has reviewed the non-audit services provided by the EA and is satisfied that the nature and extent of such services would not prejudice the independence of the EA.

<i>Fees Paid / Payable to the EA for FY2022</i>		
	<b>S\$</b>	<b>% of total</b>
<b>Audit fees</b>	525,132	97.57
<b>Non-audit fees</b>		
- Tax advice advisory	13,100	2.43
	<b>538,232</b>	<b>100</b>

Notwithstanding the volume of non-audit services rendered to the Company, the AC is satisfied that the EA remains independent after considering the following:

- That all relationships and/or arrangements between the audit firm and the Company that may reasonably be thought to affect the EA's objectivity and as disclosed by the audit engagement partner did not impair the independence and objectivity of the EA; and
- The audit engagement partner has confirmed that, in his professional judgment, the audit firm is independent.

The AC also periodically receives updates on changes in accounting standards provided by the EA and circulated to members of AC.

There is no disagreement between the Board and AC regarding the selection, appointment, resignation or dismissal of the EA. In appointing the EA, the AC evaluates the performance of the EA, taking into consideration the Audit Quality Indicators Disclosure Framework published by the Accounting and Corporate Regulatory Authority.

## CORPORATE GOVERNANCE REPORT

As part of the Group's initiatives in ongoing good corporate governance, the Company is of the view that it would be appropriate and timely to effect a change of Auditors of the Company. The Directors are of the view that it would be in the best interests of the Company to consider a rotation to the present auditors of the Company. The AC had recommended, and the Board had approved the nomination of Deloitte & Touche LLP as the Company's external auditor for the financial year ending 31 December 2023, subject to the approval of shareholders. Please refer to the Change of Auditors Appendix to this annual report for further details.

### *Whistle-blowing Policy*

The Company has in place a whistle-blowing policy. The Company's staff and any other persons may, in confidence, raise concerns about possible improprieties in matters of financial reporting or other matters relating to the Company and its officers by submitting to the AC a whistle-blowing report to [whistleblowing@rexih.com](mailto:whistleblowing@rexih.com), as stated on the Company's webpage [https://investor.rexih.com/whistle\\_blowing\\_policy.html](https://investor.rexih.com/whistle_blowing_policy.html). Information received will be treated with confidentiality and the identity of the whistle-blowers will be protected. Whistleblowing reports made in good faith will be handled and investigated by the AC Chairman, who is an independent director. The whistle-blowing policy sets out the Company's commitment to ensure the protection of the whistleblower's identity and against any detrimental or unfair treatment against the whistleblower. All confidential information will only be available to the independent directors of the AC.

The AC is responsible for oversight and monitoring of whistleblowing and has ensured that arrangements are in place for such concerns to be raised and independently investigated, and for appropriate follow-up action to be taken. The details of the policy have been disseminated and made available to all parties concerned in the Company's code of conduct. There have not been any whistle-blowing reports during FY2022.

### *Audit Committee Activities*

During the year, the AC reviewed the financial statements of the Group before the announcement of the Group's half-year and full-year results. In the process, the AC reviewed the key areas of management's estimates and judgement applied for key financial matters including impairment testing, adequacy of provisioning and disclosure, the application of critical accounting policies and any other significant matters that might affect the integrity of the financial statements. The AC has considered the report from the EA, including their findings on the key areas of audit focus.

Significant matters that were discussed with Management and the EA have been included as key audit matters ("**KAMs**") in the audit report for the financial year ended 31 December 2022. Refer to pages 155 to 157 of this Annual Report.

In line with the terms of reference of the AC, the following activities were carried out by the AC during FY2022 in the discharge of its functions and duties including the deliberation and review of:

- The unaudited half-year and full year financial results of the Group and announcements prior to submission to the Board for approval and release on the SGXNet;
- The quarterly announcement on the use of funds / cash by mineral, oil and gas companies;
- The internal and external audit plans in terms of their scope of audit prior to their commencement of their annual audit;
- The EA's report in relation to audit and accounting issues arising from the audit;
- The IA's finding report including internal control processes and procedures;

## CORPORATE GOVERNANCE REPORT

- The adequacy and effectiveness of the Company's system of risk management and internal controls, including financial, operational, compliance and information technology controls and reporting the findings to the Board;
- The audited financial statements of the Group prior to submission to the Board of Directors for consideration and approval;
- The declaration of final dividend for FY2022 and recommendation to the Board for approval;
- The external audit and internal audit fees for FY2022 and recommendation to the Board for approval;
- The audit fees paid/payable to the external auditors of the Group including non-audit fees and nature of non-audit services;
- The quality of the EA across a number of evaluation criteria, including measures of relevance and quality of its works as well as its independence and re-appointment of the EA and recommendation to the Board for approval; and
- Interested person transactions falling within scope of Chapters 9 and 10 of the Listing Rules and any potential conflicts of interests.

### ***Internal Audit***

The Company's internal audit function was outsourced to RSM Risk Advisory Pte Ltd ("**RSM**") on a project basis in 2022, and RSM reported directly to the AC and administratively to the CEO. The AC is responsible for the hiring, removal, evaluation and compensation of the accounting or auditing firm or corporation which the internal audit function of the Company is outsourced to.

The AC reviews and approves the internal audit plan to ensure the adequacy of the scope of audit. The internal audit plan complements that of the EA and together forms a robust risk-based audit approach to facilitate the AC's review of the adequacy and effectiveness of the Group's risk management and internal control systems.

The AC is satisfied that RSM is able to discharge its duties effectively as it:

- is adequately qualified, given that the partner/head of the internal audit and staff assigned to the internal audit of the Company are members of the Institute of Internal Auditors and it adheres to standards set by internationally recognised professional bodies, including the Standards for the Professional Practice of Internal Auditing set by The Institute of Internal Auditors;
- is adequately resourced to carry out the Company's internal audit, which is led by Mr Dennis Lee, who has over 20 years of professional experience, and has extensive experience providing advisory solutions for numerous listed companies in the area of sustainability reporting and consultancy on climate change impact measures; and
- has the appropriate standing in the Company, given, *inter alia*, its involvement in certain AC meetings and its unfettered access to all the Group's documents, records, properties and personnel, including direct access to the AC.

The primary functions of the IA are to:

- (a) Assess if adequate systems of internal controls are in place to protect the funds and assets of the Group and to ensure control procedures are complied with;

## CORPORATE GOVERNANCE REPORT

- (b) Conduct regular in-depth audits of high-risk areas; and
- (c) Identify and recommend improvement to internal control procedures, where required.

The AC has reviewed the report submitted by RSM on internal procedures, the EA's report and the internal controls in place, and is satisfied that there are adequate internal controls in the Company.

The AC will review on an annual basis the adequacy and effectiveness of the internal audit function.

The AC had reviewed and is of the view that the internal audit function is adequate and effective in FY2022.

### SHAREHOLDER RIGHTS AND ENGAGEMENT

#### Shareholder Rights and Conduct of General Meetings

**Principle 11** *The company treats all shareholders fairly and equitably in order to enable them to exercise shareholders' rights and have the opportunity to communicate their views on matters affecting the company. The company gives shareholders a balanced and understandable assessment of its performance, position and prospects.*

#### Shareholder Rights

The Company treats all shareholders fairly and equitably, and recognises, protects and facilitates the exercise of shareholders' rights and continually reviews and updates such governance arrangements.

The Company is committed to making timely, full and accurate disclosure to shareholders and the public. All information on the Company's new initiatives which would be likely to materially affect the price or value of the Company's shares will be promptly disseminated via SGXNet to ensure fair communication with shareholders.

The Company has endeavoured to provide a longer notice period of 28 days for its Annual General Meetings and Extraordinary General Meetings over the years.

11.1 The Company provides shareholders with the opportunity to participate effectively in and vote at general meetings of shareholders and informs them of the rules governing general meetings of shareholders.

Shareholders are encouraged to attend the AGM/EGM to ensure a high level of accountability and to stay apprised of the Group's strategy and goals. Shareholders are given the opportunity to raise questions and clarify any issues that they may have relating to the resolutions to be passed. Notice of the General Meetings will be announced on SGXNet and posted on the Company's website <https://www.rexih.com>.

An independent polling agent is appointed by the Company for general meetings. The polling rules, including the voting procedures that govern the general meeting of shareholders, will be explained during the general meetings. The Company ensures that shareholders are given the opportunity to participate effectively in and vote at general meetings.

## CORPORATE GOVERNANCE REPORT

- 11.2 The Company tables separate resolutions at general meetings of shareholders on each substantially separate issue unless the issues are inter-dependent and linked, so as to form one significant proposal. If a scenario arises where the resolutions are inter-conditional, it is the Company's current intention to explain the reasons and material implications in the notice of meeting.

The Company typically ensures that there are separate resolutions at general meetings on each distinct issue.

All resolutions are put to vote by poll, and their detailed results will be announced via SGXNet on the same day after the conclusion of the general meeting. Electronic poll voting has been adopted since 2017 so as to better reflect shareholders' interest and ensure greater transparency in the voting process. An independent scrutineer is also appointed for the electronic poll voting process. Votes cast for and against each resolution will be tallied and displayed live-on-screen to shareholders or their appointed proxies immediately after each poll had been conducted at the meeting.

- 11.3 The Company requires all Directors (including the respective chairpersons of the Board Committees) and senior management, to be present at all general meetings of shareholders, unless in cases of exigencies. The EA is also required to be present to address shareholders' queries about the conduct of audit and the preparation and content of the independent auditor's report. Directors' attendance at the general meetings held in the financial year ended 31 December 2022 is tabled on page 95 of this Annual Report. All Directors attended the general meetings held in 2022.

- 11.4 The Company's Constitution allows for abstentia voting (including but not limited to the voting by mail, electronic mail or facsimile). As the authentication of shareholder identity and other related security and integrity issues still remains a concern, the Company has decided for the time being, not to implement absentia voting methods such as voting via mail, electronic mail or facsimile. A shareholder is entitled to attend and vote or to appoint not more than two proxies who need not be a shareholder of the Company, to attend and vote at the meetings on his behalf.

The Company's Constitution allows (a) each shareholder who is not a relevant intermediary the right to appoint up to two proxies and (b) each shareholder who is a relevant intermediary to appoint more than two proxies to attend, speak and vote on their behalf in general meetings. "Relevant intermediary" has the meaning ascribed to it in Section 181 of the Companies Act.

The forthcoming AGM to be held on 28 April 2023 will be convened and held by way of electronic means pursuant to the COVID-19 (Temporary Measures) (Alternative Arrangements for Meetings for Companies, Variable Capital Companies, Business Trusts, Unit Trusts and Debenture Holders) Order 2020. Alternative arrangements relating to attendance at the AGM via electronic means (including arrangements by which the meeting can be electronically accessed via live audio-visual webcast or live audio-only stream), submission of questions in advance of the AGM, addressing of substantial and relevant questions prior to the deadline submission of the AGM proxy forms, appointing proxies to attend and vote in shareholders' stead at the AGM, live voting and live question-and-answer sessions will be put in place for the AGM. The appendices, notice and proxy form of the AGM, and FY2022 Annual Report have been distributed electronically via SGXNet and the corporate website.



## CORPORATE GOVERNANCE REPORT

11.5 The Company publishes minutes of general meetings of shareholders on its corporate website <https://www.rexih.com> as soon as practicable. The minutes record substantial and relevant comments or queries from shareholders relating to the agenda of the general meeting, and responses from the Board and Management.

The Company had published the minutes of the annual general meeting and extraordinary general meeting held on 29 April 2022 and minutes of the extraordinary general meeting held on 3 March 2022 within one month from the conclusion of the respective meetings.

### 11.6 ***Dividend Policy***

On 19 October 2021 and 28 February 2022, the Company announced that it has adopted a dividend policy, which allows for dividends to be paid-out subject to eligibility, for evaluation of the Company's financial year results for the relevant period/year. The declaration and payment of dividends, if any, shall be determined at the sole discretion of the Board. Any recommendation for dividends to be paid will be tabled for Shareholders' approval at the Company's annual general meetings, if required under applicable laws.

The Board has recommended a final dividend of S\$0.005 per ordinary share for FY2022 which is subject to shareholders' approval at the forthcoming AGM.

## **Engagement with Shareholders**

***Principle 12*** ***The company communicates regularly with its shareholders and facilitates the participation of shareholders during general meetings and other dialogues to allow shareholders to communicate their views on various matters affecting the company.***

### 12.1 ***Communication with Shareholders***

The Company solicits feedback from and addresses the concerns of shareholders via the following:

- One-on-one and group meetings;
- Investor/analyst briefings;
- Conferences and roadshows;
- Annual General Meetings and Extraordinary General Meetings; and
- Responses to email queries.

In 2022, the Company issued more than 88 announcements and press releases and conducted one-on-one and group meetings, as well as conference calls, with local and foreign investors or analysts, as well as with the media.

Apart from the SGXNet announcements and its Annual Report, the Company updates shareholders on its corporate developments through its corporate website at <https://www.rexih.com> and its investor relations webpage at <https://investor.rexih.com/home.html>.

12.2 The Company has in place an Investor Relations policy which is executed by a dedicated investor relations team, which allows for an ongoing exchange of views, so as to actively engage and promote regular, effective and fair communication with shareholders.

## CORPORATE GOVERNANCE REPORT

12.3 The Company's Investor Relations policy sets out the mechanism through which shareholders may contact the Company with questions and through which the Company may respond to such questions. Contact details to the Company's investor relations team (ir@rexih.com) are available on the Company's corporate website <https://www.rexih.com>. Shareholders may contact the Lead Independent Director at [independent.director@rexih.com](mailto:independent.director@rexih.com).

The Company announces the unaudited condensed financial statements of the Company and the Group on a half yearly basis. As a mineral, oil and gas company, the Company will provide quarterly updates on its use of funds as required under Listing Rules 705(6) and 705(7). The Company also provides timely updates on its operations whenever there are material developments.

### MANAGING STAKEHOLDER RELATIONSHIPS

#### Engagement with Stakeholders

**Principle 13** *The Board adopts an inclusive approach by considering and balancing the needs and interests of material stakeholders, as part of its overall responsibility to ensure that the best interests of the company are served.*

13.1 The Company has arrangements in place to identify and engage with its material stakeholder groups and to manage its relationships with such groups. Further details can be found in the Sustainability Report section of this Annual Report.

13.2 The Company has disclosed in this Annual Report, its strategy and key areas of focus in relation to the management of stakeholder relationships during the reporting period. Further details can be found in the Sustainability Report section of this Annual Report.

13.3 The Company maintains a current corporate website, <https://www.rexih.com>, to communicate and engage with stakeholders. The Company's profile, latest news and announcements, share price information, publications such as annual reports, qualified person's reports, fact sheets and presentations can be accessed on the corporate website. Investors can also opt for email alerts on the Company's latest announcements.

## CORPORATE GOVERNANCE REPORT

### COMPLIANCE WITH APPLICABLE LISTING RULES

#### *Appointment of Auditors*

1207(6)(c) The Company confirms its compliance to Listing Rules 712 and 715. Significant foreign subsidiaries are audited by KPMG LLP, Singapore for consolidation purpose, and other member firms of KPMG International. Both KPMG LLP and the audit partner-in-charge have the relevant experience in providing audit services to various clients in the oil and gas industry. Other foreign subsidiaries are registered BVI companies that have no operational activities in FY2022.

#### 1207(8) *Material Contracts*

Save as announced via SGXNet on 30 December 2022, in respect of the various interested persons' transactions entered into between the Group and certain interested persons, there were no material contracts or loans entered into by or taken up by the Group involving the interest of the CEO, any Directors, or controlling shareholders which are either still subsisting at the end of FY2022 or if not then subsisting, entered into since the end of the previous financial year ended 31 December 2021.

#### 1207(10) *Confirmation of Adequacy of Internal Controls*

The Board and the AC are of the opinion that the internal controls are adequate and effective to address the financial, operational, compliance and information technology risks, and risk management systems which the Group considers relevant and material to its current business scope and environment based on the following:

- Assurance has been received from the CEO, the CFO and key management personnel that are responsible for the adequacy and effectiveness of the Group's risk management and internal control systems;
- An internal audit has been done by the IA and significant matters highlighted to the AC and Management were appropriately addressed;
- Management regularly evaluates, monitors and reports to the AC and the RMC on material risks;
- Discussions were held between the AC and auditors in the absence of the Management to review and address any potential concerns;
- An enterprise risk management framework is in place to identify, manage and mitigate significant risks; and
- Risk appetite statements with tolerance limits have been approved by the Board to contain risks within acceptable levels and are monitored on a quarterly basis.

The Board notes that the system of internal controls and risk management provides reasonable, but not absolute assurance that the Group will not be adversely affected by any event that could be reasonably foreseen as it works to achieve its business objectives. In this regard, the Board also notes that no system of internal controls and risk management can provide absolute assurance against the occurrence of material errors, poor judgment in decision making, human error, losses, fraud or other irregularities.

## CORPORATE GOVERNANCE REPORT

- 1207(10A) There is no family relation between the Executive Chairman and the CEO of the Company.
- 1207(10C) The AC is of the view that the Company's internal audit function is independent, effective and adequately resourced.

### 1207(17) ***Interested Persons' Transactions ("IPT")***

The Company does not have an IPT Mandate. The aggregate value of IPTs for FY2022 disclosed in accordance with Rule 907 of the Listing Rules was as follows:

Name of interested person	Nature of relationship	Aggregate value of all interested person transactions during the financial year under review (excluding transactions less than \$100,000 and transactions conducted under shareholders' mandate pursuant to Rule 920)	Aggregate value of all interested person transactions conducted under shareholders' mandate pursuant to Rule 920 (excluding transactions less than \$100,000)
		US\$'000	US\$'000
Xer Technologies Pte. Ltd. (" <b>Xer</b> ")	Xer is held by Cresta and Limea at 42% and 15% respectively	4,000*	–
Moroxite AB (" <b>Moroxite</b> ")	Moroxite is 39.6% held by a company owned by Dr Lars Lidgren, brother to Dr Karl Lidgren and Mr Hans Lidgren	4,120	–

**Notes:**

Dr Karl Lidgren and Mr Hans Lidgren are controlling shareholders of the Company with a 34.71% deemed interest in the Company held through Limea Ltd. ("**Limea**"), in which each of Mr Hans Lidgren and Cresta Group Ltd ("**Cresta**") have a 50% shareholding interest respectively. Cresta is in turn wholly-owned by Dr Karl Lidgren.

\*Subject to the achievement of certain technical and sales milestones by Xer.

Completion of the IPT entered into with Moroxite is subject to conditions, including receipt of shareholders' approval.

Save as disclosed above, there were no other IPTs that were more than S\$100,000 entered into by the Group in FY2022.

The Company has adopted an internal policy in respect of any transactions with an interested person (as defined in the Listing Rules) and has established procedures for the review and approval of all IPTs entered into by the Group. The AC reviews the rationale and terms of the Group's IPTs, with the view that the IPTs should be on normal commercial terms, at arm's length basis and are not prejudicial to the interests of its minority shareholders.

## CORPORATE GOVERNANCE REPORT

As part of the Company's policy, Directors are required to disclose to the Board all actual and potential conflicts of interest. A Director shall recuse himself or herself from discussions and abstain from voting on resolutions regarding any contract, arrangement or any other transaction in which he or she has any personal material interest, directly or indirectly.

1207(19)

### ***Dealing in Securities***

The Company and its subsidiaries have adopted an internal policy which prohibits the Directors and officers (including employees) from dealing in the securities of the Company while in possession of price-sensitive information.

The Company, its Directors and officers (including employees) of the Company and its subsidiaries are also discouraged from dealing in the Company's securities on short-term considerations and are prohibited from dealing in the Company's securities during the period beginning one month before the announcement of the Company's half-year and full-year financial statements, and ending on the date of the announcement of the relevant results.

1207(20)

### ***Use of Proceeds Raised from Placement Exercise***

The Company had on 6 November 2013, completed a placement of 70 million new ordinary shares at an issue price of S\$0.755 per share (the "**2013 Placement**"), raising net proceeds of S\$50.87 million (after deducting placement expenses of S\$1.98 million). As at the date of this report, the Company had utilised all the 2013 Placement proceeds except for the amount allocated to the share buyback mandate of S\$5.96 million.

The Company had utilised S\$0.99 million in relation to the share buyback exercise in the financial year ended 2019. No share buybacks were conducted in FY2020, FY2021 and FY2022. The ending balance of the amount allocated to the share buyback mandate as at 31 December 2022 and the date of this report was S\$4.97 million.

720(6)

### ***Additional Information on Directors Seeking Re-election***

Pursuant to Listing Rule 720(6), the additional information as set out in Appendix 7.4.1 of the Listing Rules relating to the retiring Directors who are submitting themselves for re-election, is disclosed below and to be read in conjunction with their respective biographies under the section entitled "Board of Directors" of this Annual Report:

## CORPORATE GOVERNANCE REPORT

	<b>Dan Broström</b>	<b>Sin Boon Ann</b>	<b>Heng Su-Ling Mae</b>	<b>John d'Abo</b>	<b>Dr Mathias Lidgren</b>
Date of Appointment	11 January 2013	26 June 2013	4 May 2022	4 May 2022	4 May 2022
Date of last re-appointment (if applicable)	23 April 2021	23 April 2021	Not Applicable	Not Applicable	Not Applicable
Age	79	65	52	54	41
Country of principal residence	Singapore	Singapore	Singapore	United Kingdom	Sweden
The Board's comments on this re-appointment	The re-election of Dan Broström was recommended by the Nominating Committee and the Board has accepted the recommendation, after taking into consideration his contributions and performance.	The re-election of Sin Boon Ann was recommended by the Nominating Committee and the Board has accepted the recommendation, after taking into consideration his independence, contributions and performance.	The re-election of Mae Heng was recommended by the Nominating Committee and the Board has accepted the recommendation, after taking into consideration her independence, contributions and performance.	The re-election of John d'Abo was recommended by the Nominating Committee and the Board has accepted the recommendation, after taking into consideration his independence, contributions and performance.	The re-election of Dr Mathias Lidgren was recommended by the Nominating Committee and the Board has accepted the recommendation, after taking into consideration his contributions and performance.
Whether appointment is executive, and if so, the area of responsibility	Executive. He leads the Board and assumes the roles and responsibilities as chairman of the Company	Non-Executive.	Non-Executive.	Non-Executive.	Non-Executive.
Job Title (e.g. Lead ID, AC Chairman, AC Member etc.)	<ul style="list-style-type: none"> <li>Executive Chairman</li> <li>Member of Audit Committee</li> <li>Member of Remuneration Committee</li> </ul>	<ul style="list-style-type: none"> <li>Lead Independent Non-Executive Director</li> <li>Chairman of Nominating and Remuneration Committees</li> <li>Member of Audit Committee</li> </ul>	<ul style="list-style-type: none"> <li>Independent Non-Executive Director</li> <li>Chairperson of Audit Committee</li> </ul>	<ul style="list-style-type: none"> <li>Independent Non-Executive Director</li> <li>Member of Nominating and Remuneration Committees</li> </ul>	<ul style="list-style-type: none"> <li>Non-Independent Non-Executive Director</li> <li>Member of Nominating Committee</li> </ul>
Professional Qualifications	Refer to section on Board of Directors at pages 10 to 13 of this annual report for details.				
Working experience and occupation(s) during the past 10 years	Refer to section on Board of Directors at pages 10 to 13 of this annual report for details.				

## CORPORATE GOVERNANCE REPORT

	<b>Dan Broström</b>	<b>Sin Boon Ann</b>	<b>Heng Su-Ling Mae</b>	<b>John d'Abo</b>	<b>Dr Mathias Lidgren</b>
Shareholding interest in the listed issuer and its subsidiaries	Direct: 11,306,075 ordinary shares (representing 0.87% shareholding interest) in Rex International Holding Limited  Subsidiaries of Rex International Holding Limited: Nil	Direct: 900,000 ordinary shares (representing 0.07% shareholding interest) in Rex International Holding Limited  Subsidiaries of Rex International Holding Limited: Nil	Direct and Deemed: Nil  Subsidiaries of Rex International Holding Limited: Nil	Direct: 128,000 ordinary shares (representing 0.01% shareholding interest) in Rex International Holding Limited  Subsidiaries of Rex International Holding Limited: Nil	Direct interest: 7,000,000 ordinary shares held through Citibank N.A. Singapore (representing 0.54% shareholding interest) in Rex International Holding Limited  Subsidiaries of Rex International Holding Limited: Nil
Any relationship (including immediate family relationships) with any existing director, existing executive officer, the issuer and/or substantial shareholder of the listed issuer or of any of its principal subsidiaries	No	No	No	No	Yes. Dr Mathias Lidgren is the son of Mr Hans Lidgren (controlling shareholder), nephew of Dr Karl Lidgren (Executive Director and controlling shareholder), and first cousin of Mr Mans Lidgren (Chief Executive Officer) and brother of Ms Lina Berntsen (Chief Technology Officer).  Mr Hans Lidgren and Dr Karl Lidgren are deemed interested in 34.71% of the Company's shares held by Limea Ltd., in which each of Mr Hans Lidgren and Cresta Group Ltd (" <b>Cresta</b> ") has a 50% shareholding interest in respectively. Cresta is in turn wholly-owned by Dr Karl Lidgren.

## CORPORATE GOVERNANCE REPORT

	<b>Dan Broström</b>	<b>Sin Boon Ann</b>	<b>Heng Su-Ling Mae</b>	<b>John d'Abo</b>	<b>Dr Mathias Lidgren</b>
Conflict of interests (including any competing business)	No	No	No	No	No
Undertaking has been submitted to the listed issuer in the form of Appendix 7.7 under Rule 720(1)	Yes	Yes	Yes	Yes	Yes
Past (for the last 5 years)	<u>Principal Commitments including Directorships</u> <ul style="list-style-type: none"> <li>• Rex South East Asia Ltd.</li> <li>• Rex Technology Management Ltd.</li> <li>• Rex US Ltd.</li> <li>• Cathay Ltd</li> </ul>	<u>Principal Commitments including Directorships</u> <ul style="list-style-type: none"> <li>• HRnet Group Limited</li> <li>• SE Hub Ltd.</li> <li>• Datapulse Technology Limited</li> <li>• At-Sunrice GlobalChef Academy Pte. Ltd.</li> <li>• DrewCorp Services Pte Ltd</li> <li>• Drew &amp; Napier LLC</li> </ul>	<u>Other Principal Commitments including Directorships</u> <ul style="list-style-type: none"> <li>• Pacific Star Development Limited</li> </ul>	<u>Principal Commitments including Directorships</u> <ul style="list-style-type: none"> <li>• Avicrisali Srl</li> <li>• Piscicola Salcioara Srl</li> <li>• Agropig Srl</li> <li>• Caviar Biotec Ltd</li> </ul>	<u>Principal Commitments including Directorships</u> <ul style="list-style-type: none"> <li>• Medical Doctor, Sahlgrenska University Hospital, Gothenburg, Sweden</li> </ul>
Present	<u>Principal Commitments including Directorships</u> <ul style="list-style-type: none"> <li>• Rex International Investments Pte. Ltd.</li> <li>• Rex Technology Investments Pte. Ltd.</li> <li>• Rex International Holding Ltd. (BVI)</li> <li>• Cathay (Venture) Pte Ltd</li> </ul>	<u>Principal Commitments including Directorships</u> <ul style="list-style-type: none"> <li>• Sarine Technologies Ltd</li> <li>• The Trendlines Group Ltd</li> <li>• Balkan Holdings Pte. Ltd</li> <li>• Healthway Medical Corporation Limited</li> <li>• The Farrer Park Company Pte. Ltd.</li> </ul>	<u>Principal Commitments including Directorships</u> <ul style="list-style-type: none"> <li>• Novo Tellus Alpha Acquisition</li> <li>• Grand Venture Technology Limited</li> <li>• Chuan Hup Holdings Limited</li> <li>• HRnet Group Limited</li> <li>• Ossia International Limited</li> </ul>	<u>Principal Commitments including Directorships</u> <ul style="list-style-type: none"> <li>• Erland Advisors Ltd</li> <li>• Moroxite Holding Pte. Ltd.</li> </ul>	<u>Principal Commitments including Directorships</u> <ul style="list-style-type: none"> <li>• Propatria AB</li> <li>• Rotationsplast i Munka-Ljungby AB</li> <li>• Caithness Fastighets AB</li> <li>• Förvaltningsaktiebolaget Maple</li> <li>• Trolleholms Slott AB</li> <li>• Captiosus AB</li> <li>• Strominnate Therapeutics AB</li> </ul>



## CORPORATE GOVERNANCE REPORT

	<b>Dan Broström</b>	<b>Sin Boon Ann</b>	<b>Heng Su-Ling Mae</b>	<b>John d'Abo</b>	<b>Dr Mathias Lidgren</b>
	<ul style="list-style-type: none"> <li>• Havalina Pte Ltd</li> <li>• Moroxite Holding Pte. Ltd.</li> <li>• Xer Technologies Pte. Ltd.</li> </ul>	<ul style="list-style-type: none"> <li>• W Capital Markets Pte. Ltd.</li> <li>• TIH Limited</li> <li>• At-Sunrice (Holdings) Pte. Ltd.</li> <li>• Esseplore Pte. Ltd.</li> <li>• Singapore Centre for Social Enterprise Ltd.</li> <li>• OUE Limited</li> <li>• CSE Global Limited</li> <li>• Tampines Central Community Foundation Limited</li> <li>• Drew &amp; Napier LLC</li> </ul>	<ul style="list-style-type: none"> <li>• Apex Healthcare Berhad</li> <li>• Drew &amp; Lee Investment (Private) Limited</li> <li>• Drew &amp; Lee Holding (Private) Limited</li> <li>• Drew &amp; Lee Land Pte. Ltd.</li> </ul>		<ul style="list-style-type: none"> <li>• Moroxite Holding Pte. Ltd.</li> <li>• Moroxite T AB</li> <li>• Medical Doctor, Skane University Hospitals, Lund, Sweden</li> <li>• Postdoctoral Researcher, Division of Molecular Medicine and Gene Therapy, Department of Laboratory Medicine, Lund University, Lund, Sweden</li> </ul>
(a) Whether at any time during the last 10 years, an application or a petition under any bankruptcy law of any jurisdiction was filed against him or against a partnership of which he was a partner at the time when he was a partner or at any time within 2 years from the date he ceased to be a partner?	No	No	No	No	No

## CORPORATE GOVERNANCE REPORT

	<b>Dan Broström</b>	<b>Sin Boon Ann</b>	<b>Heng Su-Ling Mae</b>	<b>John d'Abo</b>	<b>Dr Mathias Lidgren</b>
(b) Whether at any time during the last 10 years, an application or a petition under any law of any jurisdiction was filed against an entity (not being a partnership) of which he was a director or an equivalent person or a key executive, at the time when he was a director or an equivalent person or a key executive of that entity or at any time within 2 years from the date he ceased to be a director or an equivalent person or a key executive of that entity, for the winding up or dissolution of that entity or, where that entity is the trustee of a business trust, that business trust, on the ground of insolvency?	No	No	No	No	No
(c) Whether there is any unsatisfied judgment against him?	No	No	No	No	No

## CORPORATE GOVERNANCE REPORT

	<b>Dan Broström</b>	<b>Sin Boon Ann</b>	<b>Heng Su-Ling Mae</b>	<b>John d'Abo</b>	<b>Dr Mathias Lidgren</b>
(d) Whether he has ever been convicted of any offence, in Singapore or elsewhere, involving fraud or dishonesty which is punishable with imprisonment, or has been the subject of any criminal proceedings (including any pending criminal proceedings of which he is aware) for such purpose?	No	No	No	No	No
(e) Whether he has ever been convicted of any offence, in Singapore or elsewhere, involving a breach of any law or regulatory requirement that relates to the securities or futures industry in Singapore or elsewhere, or has been the subject of any criminal proceedings (including any pending criminal proceedings of which he is aware) for such breach?	No	No	No	No	No

## CORPORATE GOVERNANCE REPORT

	<b>Dan Broström</b>	<b>Sin Boon Ann</b>	<b>Heng Su-Ling Mae</b>	<b>John d'Abo</b>	<b>Dr Mathias Lidgren</b>
(f) Whether at any time during the last 10 years, judgment has been entered against him in any civil proceedings in Singapore or elsewhere involving a breach of any law or regulatory requirement that relates to the securities or futures industry in Singapore or elsewhere, or a finding of fraud, misrepresentation or dishonesty on his part, or he has been the subject of any civil proceedings (including any pending civil proceedings of which he is aware) involving an allegation of fraud, misrepresentation or dishonesty on his part?	No	No	No	No	No
(g) Whether he has ever been convicted in Singapore or elsewhere of any offence in connection with the formation or management of any entity or business trust?	No	No	No	No	No

## CORPORATE GOVERNANCE REPORT

	Dan Broström	Sin Boon Ann	Heng Su-Ling Mae	John d'Abo	Dr Mathias Lidgren
(h) Whether he has ever been disqualified from acting as a director or an equivalent person of any entity (including the trustee of a business trust), or from taking part directly or indirectly in the management of any entity or business trust?	No	No	No	No	No
(i) Whether he has ever been the subject of any order, judgment or ruling of any court, tribunal or governmental body, permanently or temporarily enjoining him from engaging in any type of business practice or activity?	No	No	No	No	No
(j) Whether he has ever, to his knowledge, been concerned with the management or conduct, in Singapore or elsewhere, of the affairs of :  (i) any corporation which has been investigated for a breach of any law or regulatory requirement governing corporations in Singapore or elsewhere; or	No	Yes.  Mr Sin Boon Ann has been the Independent Chairman of Healthway Medical Corporation (" <b>HMC</b> ") since 26 April 2019. HMC had received enquiries and communicated with the Singapore Exchange Regulation Pte. Ltd. in relation to its obligations under Catalist Listing Rule 703(4) (a) read with paragraph 27(a) of the Corporate Disclosure Policy.	No	No	No

## CORPORATE GOVERNANCE REPORT

	Dan Broström	Sin Boon Ann	Heng Su-Ling Mae	John d'Abo	Dr Mathias Lidgren
		<p>This arose from certain inaccurate disclosures in HMC's annual report for the financial year ended 31 December 2019 ("<b>AR 2019</b>") pertaining to the re-election of Mr Sin and the appointment of Ms Poh Mui Hoon, which were corrected in HMC's subsequent corrigendum after the inadvertent errors first discovered. The AR 2019 had been announced by HMC on SGXNET on 15 April 2020 and the aforesaid disclosures were subsequently revised and corrected by way of a corrigendum to the AR 2019 announced by HMC on SGXNET on 22 June 2020.</p>			
(ii) any entity (not being a corporation) which has been investigated for a breach of any law or regulatory requirement governing such entities in Singapore or elsewhere; or	No	No	No	No	No

## CORPORATE GOVERNANCE REPORT

	<b>Dan Broström</b>	<b>Sin Boon Ann</b>	<b>Heng Su-Ling Mae</b>	<b>John d'Abo</b>	<b>Dr Mathias Lidgren</b>
(iii) any business trust which has been investigated for a breach of any law or regulatory requirement governing business trusts in Singapore or elsewhere; or	No	No	No	No	No
(iv) any entity or business trust which has been investigated for a breach of any law or regulatory requirement that relates to the securities or futures industry in Singapore or elsewhere,	No	No	No	No	No
with any matter occurring or arising during that period when he was so concerned with the entity or business trust?					

## CORPORATE GOVERNANCE REPORT

	<b>Dan Broström</b>	<b>Sin Boon Ann</b>	<b>Heng Su-Ling Mae</b>	<b>John d'Abo</b>	<b>Dr Mathias Lidgren</b>
(k) Whether he has been the subject of any current or past investigation or disciplinary proceedings, or has been reprimanded or issued any warning, by the Monetary Authority of Singapore or any other regulatory authority, exchange, professional body or government agency, whether in Singapore or elsewhere?	No	No	No	No	No